MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
A Phase 2/[ADDRESS_408822] Respi[INVESTIGATOR_330800], in High-risk Children (MEDLEY)
Spons or Protocol N u m b er:
Applica t io n  N u m b er:
Inve s tigatio n al Pro du ct:
Spons or :D5290C00005
IND number 118524
MEDI8897
MedImmune, LLC, a wholly owned s ub s idiary of
[COMPANY_008] P LC, , Gaither s bu r g,
Maryland, [ZIP_CODE], U S A
Med ical Mo n itor:
, AstraZe n eca
Contract Re s earc h  Orga n izatio n :
Protocol Hi s tory, Date : Original P rotocol, 05Apr2019
Protocol Amendment 1, 31 M ar2021
This document contain s  trade s ecret s  and commercial information that i s  privileged or
confidential and may not be di s clo s ed without prior authorization from M edImmune.
CONFIDENTIAL AND PROPRIETARY 1 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
PROTOCOL  AMENDMENT  SUMMARY  OF  CHANGES  TABLE
Ame ndm e n t 1 (31Mar2021)
Overall Ratio n ale for t h e Ame nd me n t
The principal rea s on for thi s  amendment wa s  to update the s ample s ize for target enrollment,
introduce a primary analy s i s  and S ea s on [ADDRESS_408823] s,
4.8.2 S a mp le  S ize ,
4.8.4 Eff icac y
Synops i s,
4.8 S tati s tical  Ev al u ati on
Synops i s,
4.8.4 Eff icac y
Synops i s,
[IP_ADDRESS] H ealt h ca r e
Resour ce  U tilizati on a nd
Care g i v e r Burd e n
[IP_ADDRESS] R e por ti ng Produ ct
Comp lai n t sDescri pt i on of Chang e
Update d t h e  m e d ical  mon it or
inform ati on
Remov e d hypo t h e s e s s ecti on w it h
clarif icati on
Update d t h e  s a mp le  s ize
Adde d pr i m a ry a n al ys i s a nd S ea son [ADDRESS_408824] s w it h at  lea s t  1 on e  m e d icall y
attend e d RSV LRTI (pro t o c o l  d e f i n e d) ;
other subgroups w e r e  r e mov e d
Remov e d t h e  f a x numb e r a nd t h e
[PHONE_2695]-MEDI-411 (+[PHONE_2693])
phon e  numb e rBrief Rat i ona le
Chang e  i n m e d ical  mon it or for t h i s
study
The s t udy i s d e s c r i p ti v e  by d e s i gn
and t h e r e  i s no form al  hypo t h e s i s
testing, t h e r e for e  t h e  hypo t h e s e s
section w a s r e mov e d t o a vo i d
poten tial  c onfus i on. A l so a dd e d a
clarif icati on / r ati on ale  t o d e s c r i b e
why form al  hypo t h e s i s te s ti ng for
efficac y i s no t  f ea s i b le .
Give n t h e  c h alle ng e  of s t udy
enroll m e n t  du e  t o t h e  COVID-19
pand e m ic , t h e  s a mp le  s ize  w a s
reduce d from or i g i n all y p la nn e d i n
the pro t o c o l .
To all ow ea r lie r a ss e ssm e n t  of
Season 1 a nd S ea son 2 d ata
As th e  i n ci d e n ce  of m e d icall y
attend e d RSV LRTI a nd RSV
hospi[INVESTIGATOR_28689] ( a nd t h e  r ele v a n t
HRU) a r e  e xp ecte d t o b e  l ow e r i n
Season 2 ( i nf a n t ’s s ec ond RSV
season) t h a n t h at  i n S ea son 1,
comb i n i ng t h e  e v e n t s from S ea son [ADDRESS_408825] e n
summ a r ie s on t h e  mos t  i mpor ta n t
efficac y e v e n t s, wh ic h a r e  m e d icall y
attend e d RSV LRTIs (pro t o c o l
defin e d), e sp eciall y g i v e n t h at
COVID-[ADDRESS_408826]  on t h e  numb e r of RSV a nd
non-RSV LRTIs
The numb e rs r e mov e d a r e  no l ong e r
in us e
CONFIDENTIAL AND PROPRIETARY 2 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Secti on
4.8.1 G e n e r al
Cons i d e r ati ons
5.3.1 Hyp e rs e ns iti v it y,
Includ i ng An a phy la x i s,
[IP_ADDRESS] Hyp e rs e ns iti v it y,
Includ i ng An a phy la x i s
Throughou tDescri pt i on of Chang e
Adde d d e s c r i p ti on a bou t  s t r ate gy t o
main tai n t h e  b li nd
Clari f ie d hyp e rs e ns iti v it y by a dd i ng
imme d iate  ( t yp e  I)
Minor e d it or ial  r e v i s i onsBrief Rat i ona le
To ensur e  t r ial  i n te gr it y a nd t h e
blind i ng of t h e  S ea son 2 t r eat m e n t
assignm e n t  for CLD / CHD sub ject s
who w e r e  r a ndom ize d t o t h e
paliv iz um a b a rm i n S ea son 1
For cla r it y
Minor, t h e r e for e , w e r e  no t
summ a r ize d
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  COVID-19 = c oron a v i rus d i s ea s e  2019 ;
HRU = h ealt h ca r e  r e sour ce  u tilizati on ;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  RSV = r e sp i r at ory syn c y tial
virus.
CONFIDENTIAL AND PROPRIETARY 3 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
PROTOCOL  SYNOPSIS
TITLE
A Ph a s e  2 / [ADDRESS_408827] e n
(MEDLEY)
OBJECTIVES and ASSOCIATED ENDPOINTS
Type
Prima r y
Safet y
Seconda r yObjec t i v e
To ev al u ate  t h e  s a f et y a nd t o le r a b ilit y of
MEDI8897 c omp a r e d t o p ali v iz um a b
when a dm i n i s te r e d t o pr ete rm i nf a n t s
enter i ng t h ei r f i rs t  RSV s ea son a nd
childr e n w it h CLD or CHD e n te r i ng t h ei r
first a nd s ec ond RSV s ea sonEndpo i nt
Safet y a nd t o le r a b ilit y of MEDI8897 a s
assess e d by t h e  o cc urr e n ce  of all  TEAEs,
TESAEs, AESIs, a nd NOCDs
PKTo ev al u ate  s e rum c on ce n t r ati ons of
MEDI8897 a nd p ali v iz um a b• MEDI8897 a nd p ali v iz um a b s e rum
conce n t r ati ons
• MEDI8897 a nd p ali v iz um a b PK
param ete rs :  Summ a ry of s e rum
conce n t r ati ons a nd e s ti m ate d PK
param ete rs (C max , AUC, a pp a r e n t
clear a n ce , a nd t 1 / 2 , i f d ata  p e rm it )
ADA
Efficac yTo ev al u ate  ADA r e spons e s t o MEDI8897
and t o p ali v iz um a b i n s e rum
To ass e ss t h e  d e s c r i p ti v e  e ff icac y of
MEDI8897 wh e n a dm i n i s te r e d a s a  s i ng le
IM dos e  of 50 mg t o i nf a n t s < 5 kg or
100 mg t o i nf a n t s ≥ 5 kg i n t h e  f i rs t  RSV
season or a  s i ng le  200-mg IM dos e
admi n i s te r e d i n t h e  s ec ond RSV s ea son, i n
reduci ng m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) a nd
hospi[INVESTIGATOR_330801] e  t o RT-PCR- c onf i rm e d
RSV, c omp a r e d t o p ali v iz um a bIncid e n ce  of ADA t o MEDI8897 a nd
paliv iz um a b i n s e rum
• In ci d e n ce  of m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) du e  t o RT-PCR-
confi rm e d RSV t hrough 150 d a ys a f te r
Dose  1 for S ea son 1 a nd S ea son 2
• In ci d e n ce  of hosp italizati ons du e  t o
RT-PCR- c onf i rm e d RSV t hrough 150 d a ys
after Dos e  1 for S ea son 1 a nd S ea son 2
CONFIDENTIAL AND PROPRIETARY 4 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Type Obj ec t i v e Endpo i nt
Expl o r ato r y
RSV
neutr alizi ng
antibodyTo dete rm i n e  a n ti -RSV n e u t r alizi ng
antibody le v el s i n s e rum a fford e d by a
single  dos e  of MEDI8897 c omp a r e d t o
5 mon t h l y dos e s of p ali v iz um a b• An ti -RSV n e u t r alizi ng a n ti body le v el s
(IU/mL) i n s e rum for MEDI8897 r eci p ie n t s
comp a r e d t o p ali v iz um a b r eci p ie n t s
• Summ a ry of s e rum RSV n e u t r alizi ng
antibody le v el s (m a y i n cl ud e  GMT, GMFR,
Cmax, a pp a r e n t  clea r a n ce , a nd t 1 / 2 )
RSV
serol ogyTo ev al u ate  e xposur e  t o RSV by
[CONTACT_330842] i ng s e ror e spons e s t o d i ff e r e n t  RSV
protei ns i n MEDI8897 a nd p ali v iz um a b
recip ie n t s
To ev al u ate  t h e  le v el s of m ate rn al  RSV-
speci f ic  a n ti body i n MEDI8897 a nd
paliv iz um a b r eci p ie n t s• An ti body le v el s t o RSV F, G a , Gb, or N at
diffe r e n t  ti m e  po i n t s
• Ch a ng e s i n RSV a n ti body le v el s
(seror e spons e ) i nd icati ng e xposur e  t o RSV
• RSV a n ti g e n a n ti body le v el s (AbU / mL)
to mu lti p le  RSV a n ti g e ns
• Summ a ry of s e rum RSV a n ti body le v el s
(may i n cl ud e  GMT, GMFR,
seroc onv e rs i on r ate s, a pp a r e n t  clea r a n ce ,
and t 1 / 2 )
HRU a nd
careg i v e r
burde nTo ass e ss HRU a nd ca r e g i v e r burd e n for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t s• M a gn it ud e  of HRU ( e g, numb e r of
admi ss i ons t o hosp ital s a nd ICUs a nd
durati on of s ta y ;  numb e r of sub ject s who
requi r e  r e sp i r at ory suppor t  a nd
supple m e n tal  oxyg e n a nd t h e  dur ati on of
use; numb e r a nd t yp e  of ou t p atie n t  v i s it s
[eg, ER, urg e n t  ca r e , ou t p atie n t  cli n ic ] ;  a nd
numb e r of pr e s c r i p ti on a nd OTC
medicati ons a nd dur ati on of us e ) for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t s
• Ca r e g i v e r burd e n ( e g, ca r e g i v e r m i ss e d
work d a ys, sub ject  a bs e n ce  from d a y ca r e )
for sub ject s w it h m e d icall y atte nd e d LRTI
cause d by [CONTACT_937]-PCR- c onf i rm e d RSV
RSV
resista n ce
monit or i ng
RSV LRTI
after D a y 151To ch a r acte r ize  r e s i s ta n ce  t o MEDI8897
and p ali v iz um a b t hrough g e no t yp ic  a nd
pheno t yp ic  a n al ys e s
To ass e ss t h e  i n ci d e n ce  of m e d icall y
attend e d LRTI du e  t o RT-PCR- c onf i rm e d
RSV, c omp a r e d t o p ali v iz um a b a f te r
Day 151Geno t yp ic  a n al ys i s a nd sus ce p ti b ilit y of RSV
varia n t s t o n e u t r alizati on by [CONTACT_46054]8897 a nd
paliv iz um a b
Incid e n ce  of m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) du e  t o RT-PCR-
confi rm e d RSV from D a y 152 t o D a y 361 for
Season 1 a nd S ea son 2
AbU / mL = a n ti body un it  p e r mL ;  ADA = a n ti -drug a n ti body ;  AESI = a dv e rs e  e v e n t  of sp ecial  i n te r e s t;  AUC
= area  und e r t h e  c on ce n t r ati on- ti m e  c urv e  ;  CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;
Cmax  = m a x i mum obs e rv e d c on ce n t r ati on ;  ER = e m e rg e n c y room ;  GMFR = g e om et r ic  m ea n fo l d-r i s e;  GMT
= geom et r ic  m ea n tite r ;  HRU = h ealt h ca r e  r e sour ce  u tilizati on ;  ICU = i n te ns i v e  ca r e  un it;  IM =
intramus c u la r ;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  NOCD = n e w ons et  c hron ic  d i s ea s e;  OTC = ov e r-
the-c oun te r ;  PK = ph a rm ac ok i n etic;  RSV = r e sp i r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -
polym e r a s e  c h ai n r eacti on ;  t 1 / 2  = te rm i n al  h al f- li f e;  TEAE = t r eat m e n t - e m e rg e n t  a dv e rs e  e v e n t;  TESAE =
treatm e n t - e m e rg e n t  s e r i ous a dv e rs e  e v e n t .
CONFIDENTIAL AND PROPRIETARY 5 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
STUDY DESIGN
Study D5290C00005 (MEDLEY) i s a  p i vo tal  Ph a s e  2 / 3 r a ndom ize d, doub le -b li nd, p ali v iz um a b- c on t ro lle d
study t o e v al u ate  t h e  s a f et y, PK, ADA r e spons e , a nd d e s c r i p ti v e  e ff icac y for MEDI8897 i n h i gh-r i sk i nf a n t s
eligib le  t o r ecei v e  p ali v iz um a b wh e n e n te r i ng t h ei r f i rs t  or s ec ond RSV s ea son (S ea son 1 or S ea son 2,
respecti v el y). Approx i m atel y 900 p ali v iz um a b- eli g i b le  i nf a n t s e n te r i ng t h ei r f i rs t  RSV s ea son w ill  b e  e nro lle d
into on e  of 2 c ohor t s :  (1) pr ete rm c ohor t , i n cl ud i ng a pprox i m atel y 600 pr ete rm i nf a n t s (≤ 35 w ee ks g e s tati on al
age [GA]) w it hou t  CLD / CHD, or (2) CLD / CHD c ohor t , i n cl ud i ng a pprox i m atel y 300 i nf a n t s w it h CLD of
prem at ur it y or h e modyn a m icall y s i gn i f ica n t  CHD. A m i n i mum of 100 i nf a n t s w it h h e modyn a m icall y
signi f ica n t  CHD w ill  b e  e nro lle d. W it h i n eac h c ohor t , r a ndom izati on w ill  b e  s t r ati f ie d by h e m i sph e r e
(nort h e rn, sou t h e rn) a nd sub ject  a g e  at  t h e  ti m e  of S ea son 1 r a ndom izati on (≤ 3 mon t hs, > 3 t o ≤ 6 mon t hs,
> 6 mon t hs).
Season 1, P re t er m and CLD / CHD Coho r ts
All sub ject s w ill  b e  r a ndom ize d 2 : 1 t o eit h e r t h e  MEDI8897 group ( a pprox i m atel y [ADDRESS_408828] s i n t h e  CLD / CHD c ohor t ) or
paliv iz um a b group ( a pprox i m atel y [ADDRESS_408829] s i n t h e  CLD / CHD c ohor t ). Sub ject s i n t h e  MEDI8897 group w ill  r ecei v e  a
single  f i x e d IM dos e  of MEDI8897 fo ll ow e d by 4 on ce -mon t h l y IM dos e s of p lace bo. Th e  MEDI8897 dos e
level  w ill  b e  s t r ati f ie d by w ei gh t  b a nd, ie , 50 mg for i nf a n t s w ei gh i ng < 5 kg or 100 mg for i nf a n t s w ei gh i ng ≥
[ADDRESS_408830] s i n t h e  p ali v iz um a b group w ill  r ecei v e  5 on ce -mon t h l y IM dos e s of 15 mg / kg p ali v iz um a b.
Season 2, CLD / CHD Coho r t On l y
•  Sub ject s w it h CLD / CHD ≤ 24 mon t hs of a g e  who w e r e  r a ndom ize d t o t h e  MEDI8897 group for
Season 1 w ill  r ecei v e  a  s i ng le  f i x e d IM dos e  of 200 mg MEDI8897 fo ll ow e d by 4 on ce -mon t h l y
IM dos e s of p lace bo ( a pprox i m atel y [ADDRESS_408831] s).
• Sub ject s w it h CLD / CHD ≤ 24 mon t hs of a g e  who w e r e  r a ndom ize d t o t h e  p ali v iz um a b group for
Season 1 w ill  b e  r e -r a ndom ize d 1 : [ADDRESS_408832] s i n
the MEDI8897 group w ill  r ecei v e  a  s i ng le  f i x e d IM dos e  of 200 mg MEDI8897 fo ll ow e d by
4 once -mon t h l y IM dos e s of p lace bo ( a pprox i m atel y [ADDRESS_408833] s). Sub ject s i n t h e  p ali v iz um a b group w ill
recei v e  5 on ce -mon t h l y IM dos e s of 15 mg / kg p ali v iz um a b ( a pprox i m atel y [ADDRESS_408834] s).
In Sea son [ADDRESS_408835] s i n t h e  CLD / CHD c ohor t  who und e rgo ca rd iac  surg e ry w it h ca rd i opu l mon a ry
by[CONTACT_330843] a f te r r ecei p t  of Dos e  [ADDRESS_408836] s i n t h e  pr ete rm c ohor t  w ill  b e  fo ll ow e d t hrough 1 y ea r a f te r S ea son 1 / Dos e  1, a nd sub ject s i n t h e
CLD / CHD c ohor t  w ill  b e  fo ll ow e d t hrough 1 y ea r a f te r S ea son 2 / Dos e  1. Sub ject s i n t h e  CLD / CHD c ohor t
who r ecei v e  a  r e p lace m e n t  dos e  i n S ea son [ADDRESS_408837] s s ee k i ng m e d ical  atte n ti on for a
respi r at ory ill n e ss ( i n eit h e r t h e  i np atie n t  or ou t p atie n t  s etti ng) w ill  b e  e v al u ate d for LRTI, i n cl ud i ng pro t o c o l -
defin e d m e d icall y atte nd e d RSV LRTI. A ll  sub ject s e v al u ate d for LRTI w ill  h a v e  r e sp i r at ory s a mp le s
obtai n e d a nd te s te d ce n t r all y for RSV us i ng t h e  Un ite d S tate s Food a nd Drug Adm i n i s t r ati on- clea r e d a nd
Conf orm ité  Europ ée nn e  or Europ ea n Conform it y-m a rk e d i n v it ro d ia gnos tic  r eal - ti m e  RT-PCR a ss a y.
Blood s a mp le s w ill  b e  c o llecte d for PK, ADA, a nd RSV n e u t r alizi ng a n ti body a nd RSV s e ro l ogy.
TARGET SUBJECT POPULATION
Prete rm i nf a n t s e n te r i ng t h ei r f i rs t  RSV s ea son who a r e  eli g i b le  t o r ecei v e  p ali v iz um a b, a nd c h il dr e n w it h
CLD or CHD who a r e  e n te r i ng t h ei r f i rs t  RSV s ea son a nd t h e  s a m e  c h il dr e n ≤ 24 mon t hs of a g e  e n te r i ng t h ei r
second RSV s ea son
CONFIDENTIAL AND PROPRIETARY 6 of 80 T e mp late  18.0
3, 4, 5Dose  1MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
TREATMENT GROUPS AND REGIMENS
Subject s w ill  b e  r a ndom l y a ss i gn e d t o r ecei v e  s t udy drug a s d e s c r i b e d i n t h e  S t udy D e s i gn s ecti on a nd
prese n te d b el ow :
Coho r t
Prete rm
(N = 600)MEDI8897
(N = 400)Season 1
50 mg ( i f < 5 kg) or
100 mg ( i f ≥ 5 kg) IM
Dose s 2, P lace bo IMSeason 2
Not a pp lica b le
CLD / CHD
(N = 300Paliv iz um a b
(N = 200)
MEDI8897
(N = 200)
Paliv iz um a b
(N = 100)Dos e s 1,
2, 3, 4, 5
Dose  1
Dose s 2,
3, 4, 5
Dos e s 1,
2, 3, 4, 515 mg / kg IM
50 mg ( i f < 5 kg) or
100 mg ( i f ≥ 5 kg) IM
Place bo IM
15 mg / kg IMMEDI8897
(N = 200)
MEDI8897
(N = 50)
Paliv iz um a b
(N = 50)Dose  [ADDRESS_408838] bo IM
15 mg / kg IM
STATISTICAL METHODS
Samp le  S ize : W it h r e sp ect  t o s a f et y, [ADDRESS_408839] s e xpos e d t o MEDI8897 i n S ea son 1 w ill  prov i d e  a
95% prob a b ilit y of obs e rv i ng at  lea s t  1 a dv e rs e  e v e n t  (AE) i f t h e  t ru e  e v e n t  r ate  i s 0.5% ;  i f no AEs a r e
observ e d, t h i s s t udy prov i d e s 95% c onf i d e n ce  t h at  t h e  t ru e  e v e n t  r ate  i s < 0.5%. Th e  s a mp le  s ize  i s for s a f et y
consi d e r ati on.
With r e sp ect  t o e ff icac y, a pprox i m atel y [ADDRESS_408840] s w ill  b e
expos e d t o p ali v iz um a b i n S ea son 1 t o obs e rv e  num e r icall y s i m ila r e ff icac y for bo t h mono cl on al  a n ti bod ie s.
Beca us e  of t h e  r e du ce d i n ci d e n ce  of RSV d i s ea s e  i n t h i s popu lati on fo ll ow i ng t h e  i n t rodu cti on of p ali v iz um a b,
a sup e r i or it y or non- i nf e r i or it y d e s i gn i s no t  pr actical . A v ali d non- i nf e r i or it y m a rg i n ca nno t  b e  e s ta b li sh e d
due t o t h e  lac k of h i s t or ical  e ff icac y d ata  for t h e  m e d icall y atte nd e d RSV LRTI e ndpo i n t  for p ali v iz um a b.
There for e , t h e r e  i s no hypo t h e s i s te s ti ng for e ff icac y. Us i ng a n a ssump ti on of a  6% RSV LRTI r ate  i n
paliv iz um a b r eci p ie n t s, a pprox i m atel y 18 e v e n t s w ill  b e  obs e rv e d i n t h at  group. Th e  6% RSV LRTI r ate
(1.9% RSV hosp italizati ons a nd 3.9% ou t p atie n t  RSV ill n e ss) w a s b a s e d on a  pr i or s t udy i n pr ete rm i nf a n t s
with a nd w it hou t  CLD who r ecei v e d p ali v iz um a b. Assum i ng a  6% r ate  of RSV LRTI i n MEDI8897
recip ie n t s, [ADDRESS_408841] ic a l  Ana l ys e s
Ther e  a r e  3 p la nn e d a n al ys e s for t h i s s t udy :  t h e  pr i m a ry a n al ys i s, S ea son [ADDRESS_408842] 5-mon t h RSV s ea son ( ie , S ea son 1 D a y 151 v i s it ) a nd i n cl ud e  all  a v aila b le  S ea son 1 s a f et y, e ff icac y, PK,
and ADA d ata  at  t h e  ti m e  of t h e  d ata  c u t off. Th e  S ea son 2 a n al ys i s w ill  b e  c ondu cte d a f te r all  CLD / CHD
subject s h a v e  c omp lete d fo ll ow-up t hrough t h e  s ec ond 5-mon t h RSV s ea son ( ie , S ea son 2 D a y 151 v i s it ) a nd
includ e  all  a v aila b le  S ea son [ADDRESS_408843] s h a v e  c omp lete d t h e  la s t  v i s it  of t h e  s t udy a nd
includ e  all  d ata  c o llecte d i n t h e  s t udy.
Safety :  S a f et y of MEDI8897 w ill  b e  summ a r ize d by t r eat m e n t  group b a s e d on t h e  As- t r eate d Popu lati on
(defi n e d a s all  sub ject s who r ecei v e  a ny i nv e s ti g ati on al  produ ct  a n al y ze d acc ord i ng t o t r eat m e n t  r ecei v e d) for
each s ea son, a s w ell  a s for t h e  2 c ons ec u ti v e  RSV s ea sons ( ie , S ea son 1 a nd S ea son 2). For t h e  S ea son [ADDRESS_408844] s from t h e  pr ete rm c ohor t  a nd CLD / CHD c ohor t , pr e s e n te d
CONFIDENTIAL AND PROPRIETARY 7 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
by [CONTACT_3433] e  t r eat m e n t  r ecei v e d i n S ea son 1 ;  for t h e  S ea son [ADDRESS_408845] s from t h e  CLD / CHD c ohor t , pr e s e n te d by t h e  t r eat m e n t  r ecei v e d t hrough
the [ADDRESS_408846] i ng t o t h e  c urr e n t  v e rs i on of t h e  N ati on al  C a n ce r Ins tit u te  Common T e rm i no l ogy
Crite r ia  for Adv e rs e  Ev e n t s wh e r e  a pp lica b le  for p e d iat r ic  a ss e ssm e n t s. AEs w ill  b e  c od e d by M e d ical
Dicti on a ry for R e gu lat ory A cti v itie s a nd t h e  t yp e , i n ci d e n ce , s e v e r it y, a nd r elati onsh i p t o s t udy drug w ill  b e
summ a r ize d by t r eat m e n t  group. O t h e r s a f et y a ss e ssm e n t s w ill  i n cl ud e  t h e  o cc urr e n ce  of AESIs, d e f i n e d a s
AEs of hyp e rs e ns iti v it y t o s t udy drug ( i n cl ud i ng a n a phy la x i s), t hrombo c y t op e n ia , a nd i mmun e  c omp le x
disea s e  ( e g, v a s c u liti s, e ndo ca rd iti s, n e ur iti s, g l om e ru l on e phr iti s), a nd NOCDs fo ll ow i ng s t udy drug
admi n i s t r ati on.
Effic a c y :  A ll  e ff icac y summ a r ie s w ill  b e  b a s e d on t h e  In te n t - t o- t r eat  (ITT) Popu lati on (d e f i n e d a s all
random ize d sub ject s a n al y ze d acc ord i ng t o r a ndom ize d t r eat m e n t  a ss i gnm e n t ). Th e  i n ci d e n ce  of m e d icall y
attend e d RSV LRTI ( i np atie n t  a nd ou t p atie n t ) t hrough 150 d a ys pos t  Dos e  1 ( ie , dur i ng a  t yp ical  5-mon t h
RSV s ea son) i n S ea son 1, b a s e d on RSV te s t  r e su lt s (p e rform e d ce n t r all y us i ng r eal - ti m e  RT-PCR) a nd
objecti v e  pro t o c o l -d e f i n e d LRTI c r ite r ia , i s t h e  pr i m a ry e ff icac y e ndpo i n t  a nd w ill  b e  summ a r ize d by S ea son [ADDRESS_408847] s. Th e  95% c onf i d e n ce  i n te rv al  (CI) of t h e  p e r ce n ta g e  of sub ject s m eeti ng
the pr i m a ry e ff icac y e ndpo i n t  w ill  b e  pr e s e n te d by t r eat m e n t  group. In a dd iti on, t h e  i n ci d e n ce  of RSV LRTI
through [ADDRESS_408848] s i n t h e  CLD / CHD c ohor t
based on t h e  t r eat m e n t  a ss i gnm e n t s t hrough S ea son 1 a nd S ea son 2 :  ie , ( a ) MEDI8897 (S ea son 1) / MEDI8897
(Season 2), (b) p ali v iz um a b (S ea son 1) / MEDI8897 (S ea son 2), a nd ( c ) p ali v iz um a b (S ea son 1) / p ali v iz um a b
(Season 2).
The i n ci d e n ce  of RSV hosp italizati on t hrough 150 d a ys a f te r dos i ng ( ie , dur i ng t h e  5-mon t h RSV s ea son) w ill
be summ a r ize d by t r eat m e n t  group us i ng a  s i m ila r s t r ate gy a s d e s c r i b e d for RSV LRTI.
PK: Ind i v i du al  MEDI8897 a nd p ali v iz um a b s e rum c on ce n t r ati on d ata  w ill  b e  ta bu late d by t r eat m e n t  group
along w it h d e s c r i p ti v e  s tati s tic s. PK p a r a m ete rs w ill  b e  e s ti m ate d us i ng non- c omp a r t m e n tal  a n al ys i s, i f d ata
perm it .
ADA :  Th e  i n ci d e n ce  of ADA t o MEDI8897 a nd t o p ali v iz um a b w ill  b e  a ss e ss e d a nd summ a r ize d by [CONTACT_330844] e r
and p e r ce n ta g e  of sub ject s who a r e  ADA pos iti v e  by t r eat m e n t  group. Th e  i mp act  of ADA on PK, a nd
associati on w it h TEAEs a nd TESAEs, w ill  b e  a ss e ss e d.
RSV n e ut r a lizi ng ant i body :  Ind i v i du al  MEDI8897 a nd p ali v iz um a b s e rum a n ti -RSV n e u t r alizi ng a n ti body
level s w ill  b e  ta bu late d by t r eat m e n t  group al ong w it h d e s c r i p ti v e  s tati s tic s. An ti -RSV n e u t r alizi ng a n ti body
level s i n s e rum w ill  b e  summ a r ize d by g e om et r ic  m ea n tite r a nd g e om et r ic  m ea n-fo l d r i s e  a nd c orr e spond i ng
95% CI for eac h t r eat m e n t  group at  eac h v i s it . An ti -RSV n e u t r alizi ng a n ti body le v el  t 1 / 2  w ill  b e  e s ti m ate d
using non- c omp a r t m e n tal  a n al ys i s, i f d ata  p e rm it .
RSV s er o l ogy :  An al ys i s of a n ti -RSV a n ti g e ns a n ti body le v el s i n s e rum i n MEDI8897 a nd p ali v iz um a b
recip ie n t s w ill  b e  summ a r ize d by g e om et r ic  m ea n tite r a nd g e om et r ic  m ea n-fo l d r i s e  a nd c orr e spond i ng
95% CI for eac h t r eat m e n t  group at  eac h v i s it . S e ror e spons e s i n MEDI8897 a nd p ali v iz um a b r eci p ie n t s w ill  b e
determ i n e d by e x a m i n i ng t h e  fo l d-r i s e  i n a n ti bod ie s t o G a , Gb, a nd N a n ti g e ns.
HRU and c a re g i v er  bu r d e n :  Th e  HRU a nd ca r e g i v e r burd e n summ a r ie s w ill  b e  p e rform e d on t h e  ITT
Popu lati on. Th e  m a gn it ud e  of HRU ( e g, numb e r of a dm i ss i ons t o hosp ital s a nd ICUs a nd dur ati on of s ta y ;
numb e r of sub ject s who r e qu i r e  r e sp i r at ory suppor t  a nd supp le m e n tal  oxyg e n a nd t h e  dur ati on of us e;  numb e r
and t yp e s of ou t p atie n t  v i s it s, e g, ER, urg e n t  ca r e , ou t p atie n t  cli n ic;  a nd numb e r of pr e s c r i p ti on a nd OTC
medicati ons a nd dur ati on of us e ) w ill  b e  summ a r ize d ov e r all  by t r eat m e n t  group a nd for sub ject s w it h at  lea s t
one m e d icall y atte nd e d LRTI (pro t o c o l  d e f i n e d) ca us e d by [CONTACT_937]-PCR- c onf i rm e d RSV.
Car e g i v e r burd e n ( e g, ca r e g i v e r m i ss e d work d a ys, sub ject  a bs e n ce  from d a y ca r e ) for sub ject s w it h m e d icall y
atte nd e d LRTI (pro t o c o l  d e f i n e d) ca us e d by [CONTACT_937]-PCR- c onf i rm e d RSV w ill  b e  summ a r ize d by t r eat m e n t  group.
Mon i to ri ng RSV re s i stan ce  to MEDI8897 and pa li v iz umab: G e no t yp ic  a n al ys i s of t h e  fu ll - le ng t h m at ur e
F pro tei n w ill  b e  c ondu cte d on all  RSV-pos iti v e  i so late s c onf i rm e d ce n t r all y us i ng t h e  Lyr a  RSV + hum a n
meta pn e umov i rus r eal - ti m e  RT-PCR a ss a y m a nuf act ur e d by [CONTACT_107817] i d el  Corpor ati on. RSV g e no t yp ic  a n al ys i s w ill
repor t  t h e  s e qu e n ce  c h a ng e s i n t h e  m at ur e  F pro tei n from all  RSV pos iti v e  i so late s c omp a r e d t o c on te mpor a ry
RSV A a nd RSV B r e f e r e n ce  s t r ai ns. Sus ce p ti b ilit y of nov el  RSV v a r ia n t s t o MEDI8897 a nd p ali v iz um a b w ill
be te s te d a nd c omp a r e d t o c on t ro l  v i rus e s.
CONFIDENTIAL AND PROPRIETARY 8 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
RSV LRTI o cc u rri ng f r om Day 152 to Day 361 :  Th e  i n ci d e n ce  of m e d icall y atte nd e d RSV LRTI ( i np atie n t
and ou t p atie n t ) from D a y 152 t o D a y 361 for S ea son 1 a nd S ea son 2 w ill  b e  b a s e d on RSV te s t  r e su lt s
(perform e d ce n t r all y v ia  RT-PCR) a nd ob jecti v e  cli n ical  LRTI c r ite r ia  a nd w ill  b e  summ a r ize d by t r eat m e n t
group.
CONFIDENTIAL AND PROPRIETARY 9 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
TABLE  OF  CONTENTS
PROTOCOL A M END M ENT S U MM ARY O F  CHANGE S  TABLE.................................... [ADDRESS_408849] O F  ABBREVIATION S  ........ . ................................................................................. . .. 14
1
1.1
1.2
1.3
1.4
1.4.1
1.5
1.6
1.6.1
1.6.2
1.6.3
2
2.1
2.1.1
2.1.2
3
3.1
3.1.1
3.1.2
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
3.2
3.2.1
3.2.2
3.2.3
4
4.1
4.1.1
4.1.2
4.1.3
4.1.4
4.1.5
4.1.6
4.1.7
4.1.8INTRODUCTION ......................................................................................... . .. 16
Disea s e Background ...................................................................................... . .. 16
MEDI8897 Backgroun d .................................................................................... 17
Summary of Nonclinical Experience.............................................................. . .. 18
Summary of Clinical E x perience....................................................................... 18
Study D5290C00003...................................................................................... . .. 18
Rationale for Conducting the S tudy ............................................................... . .. 20
Benefit-Ri s k and Ethical A ss e ss ment ............................................................. . .. 21
Potential Benefit ............................................................................................... 21
Potential Ri s k ................................................................................................... 21
Overall Benefit-Ri s k ......................................................................................... 22
OBJECTIVE S  AND E N D P OINT S ................................................................... 22
Primary Objective and Ass ociated Endpoint ..................................................... 22
Secondary Objective s  and A ss ociated Endpoint s ............................................... 22
Exploratory Objective s  and A ss ociated Endpoint s  ............................................ 23
STUDY DE S IGN ........ . ................................................................................. . .. 24
Description of the S tudy ................................................................................... 24
Overview ..................... . .................................................................................... 24
Dosing Regimen ............................................................................................... 27
Season 1, P reterm Coh o rt and CLD/CHD Cohort.............................................. 27
Season 2, CLD/CHD C o hort............................................................................. 27
Season 1 or S ea s on 2, CLD/CHD Cohort - Replacement Do s e.......................... [ADDRESS_408850] s ................................................................................... 34
Withdrawal of Informed Con s ent for Data and Biological S ample s ................... 34
CONFIDENTIAL AND PROPRIETARY 10 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.2
4.2.1
4.2.2
4.3
4.3.1
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
4.3.2
4.3.3
4.3.4
4.3.5
[IP_ADDRESS]
[IP_ADDRESS]
4.3.6
4.3.7
4.3.8
4.4
4.5
4.5.1
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
4.5.2
4.5.3
4.5.4
4.5.5
4.5.6
4.6
4.6.1
4.6.2
4.6.3
[IP_ADDRESS]
4.7
4.7.1
4.7.2
4.8
4.8.1
4.8.2
4.8.3
[IP_ADDRESS]
4.8.4
4.8.5
4.8.5.1Schedule of S tudy P rocedure s ........................................................................... 35
Enrollment/ S creening P eriod ............................................................................ [ADDRESS_408851] Complaint s .......................................................................... 55
Additional S tudy M edication s ........................................................................ . .. 55
Labeling ........................................................................................................... 55
Storage ............................................................................................................. 55
Treatment Compliance...................................................................................... 55
Accountability .................................................................................................. 55
Treatment A ss ignment and Blinding ................................................................. 56
Method s  for A ss igning Treatment Group s ......................................................... 56
Method s  to En s ure Blinding........................................................................... . .. 56
Method s  for Unblindin g .................................................................................... 56
Unblinding in the Event of a M edical Emergency ............................................. 56
Restriction s  During the S tudy and Concomitant Treatment( s ) ........................ . .. 57
Permitted Concomitant M edication s  ................................................................. 57
Prohibited Concomitant M edication s  ................................................................ 57
Statis tical Evaluation ........................................................................................ 57
General Con s ideration s ..................................................................................... 57
Sample S ize ................................................................................................... . .. 58
Safety ............................................................................................................... 59
Analy s i s  of Adver s e Event s  ........................................................................... . .. 59
Efficacy……… ................................................................................................. 59
Analy s i s  of P harmacokinetic s  and Anti-drug Antibody..................................... 60
Pharmacokinetic Analysi s .............................................................................. . .. 60
CONFIDENTIAL AND PROPRIETARY 11 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
[IP_ADDRESS]
4.8.6
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
4.8.7
5
5.1
5.2
5.3
5.3.1
5.3.2
5.3.3
5.4
5.5
5.5.1
5.5.2
5.5.3
5.5.4
5.5.5
5.6
5.7
5.7.1
5.7.2
5.7.3
[IP_ADDRESS]
[IP_ADDRESS]
[IP_ADDRESS]
5.7.[ADDRESS_408852] Data P rotection..................................................................................... 71
CONFIDENTIAL AND PROPRIETARY 12 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
7.[ADDRESS_408853]  OF  TABLES
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11Primary Objective and A ss ociated Endpoint ............................................ 22
Secondary Objective s  and A ss ociated Endpoint s ................................... . .. 22
Exploratory Objective s  and Endpoint s ..................................................... 23
Schedule of S creening P rocedure s  ........................................................... 35
Schedule of Treatment P eriod and F ollow-up P eriod S tudy P rocedure s :
Season 1, P reterm and CLD/CHD Cohort s ............................................... 37
Schedule of Treatment P eriod and F ollow-up P eriod S tudy P rocedure s :
Season 2, CLD/CHD Cohort Only ........................................................... [ADDRESS_408854] s  Without Underlying Lung Di s ea s e....... . .. 44
Criteria for M eeting the P rotocol-defined Endpoint of M edically
Attended R S V LRTI – S ubject s  With Underlying Lung Di s ea s e (CLD o r
CHD)....................................................................................................... [ADDRESS_408855]  OF  FIGURES
Figure 1
Figure 2
Figure 3
Figure 4Study F low Diagram................................................................................ 26
Dos ing Regimen: S ea s on 1 – P reterm Cohort and CLD/CHD Cohort....... 27
Dosing Regimen: S ea s on 2 – CLD/CHD Cohort, M EDI8897 Group in
Season 1 ............. . ................................................................................. . .. 28
Dosing Regimen: S ea s on 2 – CLD/CHD Cohort, P alivizumab Group i n
Season [ADDRESS_408856]  OF  APPENDICES
Appe nd ix A
Appe nd ix BAdditional S afety Guidance ..................................................................... 77
National In s titute of Allergy and Infectiou s  Di s ea s e s  and F ood Allergy
and Anaphylaxi s  Network Guidance for Anaphylaxi s  Diagno s i s .............. 80
CONFIDENTIAL AND PROPRIETARY 13 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
LIST  OF  ABBREVIATIONS
Abbre v i at i on o r
Speci a lize d T er m
aa a m i no aci dDefin i t i on
AAP Am e r ica n A ca d e my of P e d iat r ic s
ADA a n ti -drug a n ti body
AE a dv e rs e  e v e n t
AESI a dv e rs e  e v e n t  of sp ecial  i n te r e s t
ATP As- t r eate d Popu lati on
AUC a r ea  und e r t h e  c on ce n t r ati on- ti m e  c urv e
CE Con f orm ité  Europ ée nn e
CHD c ong e n ital  h ea r t  d i s ea s e
CI c onf i d e n ce  i n te rv al
CLD c hron ic  l ung d i s ea s e
Cmax m a x i mum obs e rv e d c on ce n t r ati on
eCRF elect ron ic  ca s e  r e por t  form
EDC elect ron ic  d ata  ca p t ur e
ER e m e rg e n c y room
EU Europ ea n Un i on
F fus i on
GA g e s tati on al  a g e
GCP Good C li n ical  Pr actice
HIV hum a n i mmunod e f icie n c y v i rus
hMPV hum a n m eta pn e umov i rus
HRU h ealt h ca r e  r e sour ce  u tilizati on
ICH In te rn ati on al  Coun cil  for H a rmon i s ati on
ICU i n te ns i v e  ca r e  un it
IEC Ind e p e nd e n t  E t h ic s Comm ittee
IgG i mmunog l obu li n G
IgG1κ i mmunog l obu li n G1 k a pp a
IM i n t r a mus c u la r
IRB Ins tit u ti on al  R e v ie w Bo a rd
ITT In te n t - t o- t r eat
IV i n t r a v e nous
IWRS i n te r acti v e  w e b r e spons e  sys te m
CONFIDENTIAL AND PROPRIETARY 14 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Abbre v i at i on o r
Speci a lize d T er m
JCVI
LRTI
mAb
MEDLEY
NCI CTCAE
NOCD
OTC
PK
RRR
RSV
RT-PCR
SAE
SID
t1/2
TEAE
TESAE
[LOCATION_006]
US FDA
[LOCATION_003]
YTEProt o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Defin i t i on
Joint  Comm ittee  on V acci n ati on a nd Immun i s ati on
lowe r r e sp i r at ory t r act  i nf ecti on
mono cl on al  a n ti body
Study D5290C00005
Nation al  C a n ce r Ins tit u te  Common T e rm i no l ogy Cr ite r ia  for Adv e rs e  Ev e n t s
new ons et  c hron ic  d i s ea s e
over- t h e - c oun te r
pharm ac ok i n etic (s)
relati v e  r i sk r e du cti on
respi r at ory syn c y tial  v i rus
revers e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n r eacti on
serious a dv e rs e  e v e n t
subject  i d e n ti f icati on
termi n al  h al f- li f e
treatm e n t - e m e rg e n t  a dv e rs e  e v e n t
treatm e n t - e m e rg e n t  s e r i ous a dv e rs e  e v e n t
Unite d K i ngdom
Unite d S tate s Food a nd Drug Adm i n i s t r ati on
Unite d S tate s of Am e r ica
M257Y / S259T / T261E [M252Y / S254T / T256E t r i p le  a m i no aci d subs tit u ti on
CONFIDENTIAL AND PROPRIETARY 15 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
1 INTRODUCTION
Prevention of re s pi[INVESTIGATOR_696] s yncytial viru s  (R S V) illne ss e s  in all infant s  i s  a major public health
priority. H owever, de s pi[INVESTIGATOR_330802] 50 year s  of attempted vaccine development, there are no
licen s ed v accine s  and no approved R S V prophylaxi s  for the broader population of healthy
infant s . There are no s pecific R S V therapeutic option s  s o the current medical management is
limited t o  s upportive care.
The only currently approved prophylaxi s  for R S V, palivizumab ( S ynagi s ® ) wa s  developed by
[CONTACT_330845] i s  only indicated for u s e in high-ri s k children: preterm infant s  ≤ 35 weeks
gestational age (GA), children with chronic lung di s ea s e (CLD) of prematurity, and child r en
with hemodynamically s ignificant congenital heart di s ea s e (CHD). In addition, further
restriction s  have been implemented by [CONTACT_330846] s  on the u s e o f
palivizumab. F or example, in the United S tate s  of America (U S A) per the American Academy
of Pediatric s  (AA P ) guideline s , palivizumab i s  not recommended for healthy preterm infants
≥ 29 week s  GA ( American Academy of P ediatric s , 2014 ). In the [LOCATION_008] ([LOCATION_006]),
palivizumab i s  recommended by [CONTACT_941] J oint Committee on Vaccination and Immuni s ation
(JCVI) for preterm infant s  with CL D  or hemodynamically s ignificant, acyanotic CHD
based on the GA at birth and chronological age at the s tart of the R S V s ea s on ( J CVI, 20 1 0a,
2010b ).
1.[ADDRESS_408857] infection (LRTI) among infant s
and young children, re s ulting in annual epi[INVESTIGATOR_901] s  worldwide ( Hall et al, 2009 ; Hall, 2012 ;
Madhi et al, 2006 ; S hay et al, 1999 ; S hi et al, 2017 ; S tockman et al, 2012 ). All children,
including healthy term infant s , are at ri s k for s evere LRTI with primary R S V infection du r ing
infancy. Ninety percent of children are infected with R S V in the fir s t 2 year s  of life, and up to
40% of them will have LRTI with t h e initial epi s ode ( American Academy of P ediatric s , 2014 ;
Greenou g h et al, 2001 ; M ei ss ner, 2003 ; P arrott et al, 1973 ). R S V LRTI, characterized
predominantly a s  bronchioliti s  or pneumonia, repre s ent s  a s eriou s  illne ss  with
acute and perhap s  long-term con s e q uence s  to the developi[INVESTIGATOR_330803] s  in the s e young children
(Blanke n  et al, 2013 ). It i s  e s timate d  that R S V cau s e s  up to 90% of childhood bronchiolitis
and up to 40% of pediatric pneumonia s  (Hall, 2001 ). R S V bronchioliti s  wa s  the leading cause
of ho s pi[INVESTIGATOR_330804] s  for infant s  < 1 year of age for any rea s on between 1997 and 1999
(Leader and Kohlha s e, 2002 ). In 20 1 5, an e s timated 33.1 million (uncertainty range, 21.6 to
50.3 million) new epi s ode s  of R S V-a ss ociated LRTI occurred worldwide in children you n ge r
than 5 year s  (28% of LRTI epi s ode s ), with approximately 3.2 million (range, 2.7 to
3.8 million) epi s ode s  nece ss itating h o s pi[INVESTIGATOR_059], leading to 59,600 (range, 48,000 to 74,500 )
in-ho s pi[INVESTIGATOR_39473] s . Children younger than 1 year of age had an e s timated 2.3 million ho s pi[INVESTIGATOR_330805] s . The overall mortality due to R S V LRTI wa s  e s timated to be a s  high a s  118,200
(uncertainty range, 94,600 to 149,400)( S hi et al, 2017 ).
CONFIDENTIAL AND PROPRIETARY 16 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Although ho s pi[INVESTIGATOR_059] i s  well recognized a s  an important con s equence of R S V illne ss ,
a large percentage of the healthcare burden from R S V occur s  out s ide of the ho s pi[INVESTIGATOR_307] ( Car r oll
et al, 2008 ; Hall et al, 2009 ; P aramore et al, 2010 ) s uch that office vi s it s  and emergency
department vi s it s  are more frequent than s ub s equent ho s pi[INVESTIGATOR_059], e s pecially in healthy
infant s . The general s everity of R S V infection ob s erved among infant s  in outpatient s ettings is
almo s t a s  s evere a s  tho s e ob s erved in ho s pi[INVESTIGATOR_330806] s , including labored breathing
requirin g  s upplemental oxygen, wheezing, and fever ( Hall, 2012 ). While 95% of children
hospi[INVESTIGATOR_191546] R S V had labored r e s pi[INVESTIGATOR_1516] s , s imilar percentage s  of outpatient s  were also
observe d  to have labored re s pi[INVESTIGATOR_1516] s  (85% of children cared for in emergency departme n ts
and 73% of children treated in private practice s etting s  (Hall et al, 2009 ). The outpatient
burden a n d s everity of di s ea s e account s  for a s ignificant portion of the morbidity a ss ociated
with R SV  in all infant s .
Palivizumab i s  the only approved a g ent for R S V prophylaxi s , and it s  u s e i s  limited to
high-ri s k children. Becau s e of it s  terminal half-life (t½) of approximately 1 month, infants and
young children need to receive monthly intramu s cular (I M ) do s e s  of palivizumab throughout
the typi[INVESTIGATOR_2855] 5-month R S V s ea s on to maintain protection. Thi s  con s titute s  a s ignificant burden
on healt h care provider s  a s  well a s  the infant s /children and their familie s . Additionally, many
infant s  who receive palivizumab are unable to comply with the monthly do s ing
schedule and non-compliance ha s  been s hown to re s ult in increa s ed ri s k of ho s pi[INVESTIGATOR_059]
(Frogel et al, 2010 ; S tewart et al, 2013 ). F urthermore, the co s t of palivizumab prophylaxis has
led to additional re s triction s  being implemented by [CONTACT_330847] s , including the U S A
(American Academy of P ediatric s , 2014 ) and the [LOCATION_006] ( J CVI, 2010a , 2010b ).
1.2 MEDI8897  Background
MEDI88 9 7 i s  briefly de s cribed below. Refer to the current Inve s tigator’ s  Brochure for details.
MEDI8897 i s  a recombinant human immunoglobulin G1 kappa (IgG1 κ) monoclonal antibody
(mAb) directed again s t the prefu s ion conformation of the R S V fu s ion ( F ) protein. The
antibody ha s  been engineered with a triple amino acid s ub s titution (YTE;
M257Y/ S 259T/T261E [ M 252Y/ S 254T/T256E, according to the European Union (EU)
numberi n g s y s tem]) in the fragment cry s tallizable ( F c) region to prolong the t 1 / [ADDRESS_408858] from that bound by [CONTACT_316755]. In preclinical s tudie s , M EDI8897 wa s
> 150-fold more potent than palivizumab in vitro and approximately 9-fold more potent than
palivizumab in vivo in the cotton rat model ( Zhu et al, 2017 ). M EDI8897 i s  currently un d e r
development by M edImmune for the pa ss ive immunization of all infant s  entering their fi r st
RSV s ea s on and children with CL D  or CHD entering their fir s t and s econd R S V s ea s on f o r
the prevention of LRTI cau s ed by R S V. M EDI8897 may provide a co s t-effective opportunity
CONFIDENTIAL AND PROPRIETARY 17 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
to protect all infant s  from R S V di s ea s e ba s ed on an improvement in potency and the extended
t1/2 that is expected to s upport once-per-R S V- s ea s on do s ing.
1.3 Summary  of  Nonclinical  Experience
Toxicity, toxicokinetic s , and immunogenicity of M EDI8897 were evaluated in a Good
Laborat o ry P ractice-compliant repeat-do s e intravenou s  (IV) and I M  toxicology s tudy
conducted in cynomolgu s  monkey s.  Toxicology s tudie s  in cynomolgu s  monkey s  indicate that
there i s  no evidence of M EDI8897 toxicity in the s e animal model s .
Overall, data from
nonclinical s tudie s  do not reveal any M EDI8897-related s afety concern s .
Detail s  of the s e s tudie s  are included in the current Inve s tigator’ s  Brochure.
1.4 Summary  of  Clinical  Experience
MEDI8897 ha s  been inve s tigated in 3 completed clinical s tudie s , including a fir s t-time-in -
human P ha s e 1a s tudy in healthy adult s  ( S tudy D5290C00001), a fir s t-time-in-pediatric
Phase 1b/2a s tudy in healthy preterm infant s  ( S tudy D5290C00002), and a P ha s e 2b s afety
and efficacy s tudy in healthy preterm infant s  ( S tudy D5290C00003). M EDI8897 had a
favorable s afety profile, with generally s imilar proportion s  of treatment-emergent adver s e
event s  (TEAE s ) reported in the M EDI8897 and placebo-control group s  acro ss  the 3 s tudies.
A summary of S tudy D5290C0000 3  i s  pre s ented below. Refer to the current Inve s tigator’s
Brochure for detail s  on all M EDI8 [ADDRESS_408859] s  were 29 to < [ADDRESS_408860] s  were randomized 2:1 to receive a s ingle do s e of 50 m g  I M
MEDI8897 (n = 969) or placebo (n = 484). A total of 1,[ADDRESS_408861] s  were
CONFIDENTIAL AND PROPRIETARY 18 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
followed for approximately 360 day s  after do s ing. The s tudy wa s  completed on 06Dec2 0 18
(last s ubject la s t vi s it).
Result s  f r om the planned primary a n aly s i s  conducted after all randomized s ubject s  who
remained in the s tudy completed the Day 151 vi s it demon s trated a s tati s tically s ignificant
relative ri s k reduction (RRR) in the incidence of the primary endpoint of R S V-confirme d
LRTI (inpatient and outpatient) and the s econdary endpoint of R S V ho s pi[INVESTIGATOR_059].
Based on the primary analy s i s , the safety profile for the M EDI8897 group wa s  comparable to
the place b o group, with no identified ri s k s . Overall, of s ubject s  in the M EDI8897
group and of s ubject s  in the p lacebo group had at lea s t 1 TEAE. The majority of the
TEAE s  were mild or moderate in s everity. TEAE s  ≤ 1 day po s t do s e occurred in 2.5% of
subject s  in both group s . In compari s on to the placebo group, the M EDI8897 group had a
lower incidence of TEAE s  occurring ≤ 7 day s  po s t do s e (15.2% v s  12.5%, re s pectively),
TEAE s  ≥ Grade 3 in s everity (12.3 %  v s  7.4%, re s pectively), and treatment-emergent s erious
adver s e event s  (TE S AE s ; 16.7% v s  10.4%, re s pectively). The mo s t common TE S AE s , based
on the M EDI8897 group, were bronchioliti s  (2.1% M EDI8897, 4.2% placebo), LRTI
(1.4% M EDI8897, 2.7% placebo), pneumonia (1.4% M EDI8897, 2.1% placebo), and
bronchiti s  (1.2% M EDI8897, 2.3% placebo). None of the TE S AE s  were con s idered related to
study treatment by [CONTACT_132366] s tigator. F ive death s  were reported during the s tudy through
Day 361, including [ADDRESS_408862] s  (0.2 % ) in the M EDI8897 group and [ADDRESS_408863] s  (0.6%) in the
placebo group. None of the death s  w ere related to s tudy drug according to the inve s tigato r .
Overall, the incidence of inve s tigational product-related TEAE s  ( M EDI8897 2.3%, placebo
2.1%); adver s e event s  of s pecial intere s t (AE S I s ), including hyper s en s itivity, immune
complex di s ea s e, and thrombocytopenia ( M EDI8897 0.5%, placebo 0.6%); and new on s et
chronic di s ea s e s wa s  low and generally
compara b le between the placebo and M EDI8897 group s . AE S I s  were reported in 5 s ubjects
([ADDRESS_408864] with petechiae) in the M EDI8897 group
and [ADDRESS_408865] s  (ra s h or ra s h papular) in the placebo group. All event s  were Grade 1 in s eve r ity.
The TEAE of petechiae that wa s  reported a s  an AE S I wa s  1-day duration and wa s  reported by
[CONTACT_941] s ite inve s tigator ba s ed on de s cri p tion by [CONTACT_7071]. There were no laboratory a ss e ss ments
for the petechiae.
CONFIDENTIAL AND PROPRIETARY 19 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
TEAE s  that involved the s kin and s ubcutaneou s  ti ss ue s  (including diaper ra s h) were collected
as skin reaction s , with a few exception s  for s kin reaction s  that could be definitively diagnosed
such a s  impetigo, varicella, and s cabie s .
Following a s ingle fixed 50-mg I M  do s e of M EDI8897, over 95% of mea s urable Day 151
concentration s  were greater than the nonclinical EC 90  target of 6.8 μg/mL. The median area
under the concentration-time curve from time 0 to infinity (AUC 0- ∞ ) and e s timated apparent
t½ were 5.3 day.mg/mL (range, 3.2 to 10.2 day.mg/mL) and 56.5 day s  (range, 46.8 to
81.1 days), re s pectively.
Overall, the rate and titer s  of ADA were low, and in ADA-po s itive s ubject s  there wa s  no
effect on P K or s afety. Of the s ubject s  who had s erum s ample s  available for te s ting, AD A  was
detected po s t ba s eline in 4.3% (40/921) of s ubject s  in the M EDI8897 group and
2.8% (1 3 /466) of s ubject s  in the placebo group; with le ss  than 5% of s ubject s  in either group
being ADA po s itive at any vi s it. ADA titer s  ranged from 1:50 to 1:3,200 in the M EDI88 9 7
group and 1:50 to 1:[ADDRESS_408866]-ba s eline ADA po s itive, ADA targeting the YTE domain wa s  ob s erved in 4/17 s ubjects
on Day 151 and 10/[ADDRESS_408867] s  had ADA on Day 361.
1.5 Rationale  for  Conducting  the  Study
Prevention of R S V illne ss e s  in all infant s  i s  a major public health priority; however, de s pi[INVESTIGATOR_330807] 50 year s  of attempted vaccine development, there are no licen s ed vaccine s . While
RSV prevention exi s t s  in the form o f a s pecific R S V IgG ( S ynagi s ® , palivizumab) requiring
5 once-monthly injection s , it i s  lice ns ed only for infant s  who experience the greate s t
morbidit y  and mortality from R S V: preterm infant s  born ≤ [ADDRESS_408868] been implemented by [CONTACT_330848] s . F or example, the U S A national guideline s  provided by [CONTACT_330849] P ediatric s  (American Academy of P ediatric s , 2014 ) limit the recommendation f o r
palivizumab to (a) preterm infant s  born before 29 week s  GA who are younger than 12 months
of age at the s tart of the R S V s ea s on, (b) preterm infant s  with a GA of < 32 week s  and CLD
for the fir s t year of life with con s ideration of prophylaxi s  during the s econd year if continued
medical s upport i s  required, and (c) infant s  with hemodynamically s ignificant CHD who a r e
12 month s  of age or younger. In the [LOCATION_006], palivizumab i s  recommended by [CONTACT_941] J oint Committee
on Vaccination and Immuni s ation ( J CVI) for preterm infant s  with CLD or hemodynamically
significant, acyanotic CHD ba s ed on the GA at birth and chronological age at the s tart of the
RSV s ea s on ( J CVI, 2010a , 2010b ). M EDI8897 i s  being developed a s  a co s t-effective
opportu n ity to protect all infant s , including tho s e who currently receive palivizumab, from
RSV di s ea s e ba s ed on improved potency and an extended t 1 / 2 , which i s  expected to s uppo r t
once-per-R S V- s ea s on do s ing.
CONFIDENTIAL AND PROPRIETARY 20 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
The M EDI8897 clinical development program include s  two pi[INVESTIGATOR_22735] s tudie s  for infant s  ente r ing
their fir s t R S V s ea s on: the completed P ha s e 2b s tudy (D5290C00003) and a planned P hase 3
study (D5290C00004 [ M ELODY]). Becau s e of the s ignificant advantage of one do s e per R S V
season that M EDI8897 would provide, M edImmune recognize s  the potentially important
benefit s  for the current pediatric po p ulation receiving palivizumab who mu s t receive monthly
injections during the typi[INVESTIGATOR_2855] 5-month R S V s ea s on for protection. Therefore, thi s  P ha s e 2/[ADDRESS_408869] their origin in the
Declaration of Hel s inki and are con s i s tent with International Council for Harmoni s ation
(ICH)/Good Clinical P ractice (GCP), and applicable regulatory requirement s .
See S ection 1.4 for a s ummary of M EDI8897 clinical s afety and efficacy. M ore detailed
information about the known and e x pected benefit s  and ri s k s  of M EDI8897 can be found in
the Investigator ’ s  Brochure.
1.6.[ADDRESS_408870] of ca r e for patient s  with s eriou s  R S V illne ss  i s  s upportive ca r e.
Thus , there i s  a s ignificant unmet medical need for R S V prophylaxi s  in high-ri s k infant s  and
children. F avorable efficacy and s afety data from the P ha s e 2b S tudy D5290C00003 in
preterm infant s  who received a s ingle do s e of M EDI8897, s ugge s t that M EDI8897 may
provide an important alternative an d  co s t-effective option.
1.6.2 Potent i a l R i sk
MEDI8897 ha s  no endogenou s  target s , and no s afety concern s  were identified in nonclinical
studie s . The potential ri s k s  are ba s ed primarily on common s afety ri s k s  ob s erved with an y
immunoglobulin, including mAb s  s uch a s  palivizumab. The s e potential ri s k s  include, but a r e
not limited to, hyper s en s itivity (including anaphylaxi s ), immune complex di s ea s e,
thrombocytopenia, and injection s ite reaction s . To date, there have been no ob s erved events o f
anaphylaxi s , s ignificant hyper s en s itivity reaction s , immune complex di s ea s e, or
thrombocytopenia attributable to M EDI8897 in the clinical s tudie s . Nonethele ss , s ubjects in
MEDI8897 clinical s tudie s  will be monitored for important potential ri s k s , and routine
pharmacovigilance and ri s k minimization activitie s  will be performed accordingly.
CONFIDENTIAL AND PROPRIETARY 21 of 80 T e mp late  18.0
Safet yMEDI8897 c omp a r e d t o p ali v iz um a b wh e n
assess e d by t h e  o cc urr e n ce  of all
TEAEs, TESAEs, AESIs, a nd NOCDsMedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
1.6.[ADDRESS_408871] s  and include s  the
protocol inclu s ion and exclu s ion criteria, re s triction s  on concomitant medication during the
study, s afety monitoring (including review of all s afety data by [CONTACT_330850]), and s tudy s toppi[INVESTIGATOR_3418].
Overall, the benefit-ri s k a ss e ss ment for thi s  P ha s e 2/[ADDRESS_408872] e n w it h CLD or
CHD e n te r i ng t h ei r f i rs t  a nd s ec ond RSV
season
AESI = a dv e rs e  e v e n t  of sp ecial  i n te r e s t;  CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;
NOCD = n e w ons et  c hron ic  d i s ea s e;  RSV = r e sp i r at ory syn c y tial  v i rus ;  TEAE = t r eat m e n t - e m e rg e n t  a dv e rs e
even t;  TESAE = t r eat m e n t - e m e rg e n t  s e r i ous a dv e rs e  e v e n t .
2.1.[ADDRESS_408873] i ves  and  Assoc i ated  Endpo i nts
Table 2                S eco nd ary O b jective s  a nd  A ss ociate d  E ndp oi n t s
Type
PKObjec t i v e
To ev al u ate  s e rum c on ce n t r ati ons of
MEDI8897 a nd p ali v iz um a bEndpo i nt
• MEDI8897 a nd p ali v iz um a b s e rum
conce n t r ati ons
• MEDI8897 a nd p ali v iz um a b PK
param ete rs :  Summ a ry of s e rum
conce n t r ati ons a nd e s ti m ate d PK
param ete rs (C max , AUC, a pp a r e n t
clear a n ce , a nd t 1 / 2 , i f d ata  p e rm it )
ADATo ev al u ate  ADA r e spons e s t o MEDI8897
and t o p ali v iz um a b i n s e rumIncid e n ce  of ADA t o MEDI8897 a nd
paliv iz um a b i n s e rum
To ass e ss t h e  d e s c r i p ti v e  e ff icac y of
MEDI8897 wh e n a dm i n i s te r e d a s a  s i ng le
Efficac y IM dos e  of 50 mg t o i nf a n t s < 5 kg or
100 mg t o i nf a n t s ≥ 5 kg i n t h e  f i rs t  RSV
season or a  s i ng le  200-mg IM dos e• In ci d e n ce  of m e d icall y atte nd e d LRTI
(inpatie n t  a nd ou t p atie n t ) du e  t o
RT-PCR- c onf i rm e d RSV t hrough
150 d a ys a f te r Dos e  1 for S ea son 1 a nd
Season 2
CONFIDENTIAL AND PROPRIETARY 22 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 2Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Seco nd ary O b jective s  a nd  A ss ociate d  E ndp oi n t s
Type Obj ec t i v e Endpo i nt
admi n i s te r e d i n t h e  s ec ond RSV s ea son, i n• In ci d e n ce  of hosp italizati ons du e  t o
reduci ng m e d icall y atte nd e d LRTI ( i np atie n t            RT-PCR- c onf i rm e d RSV t hrough
and ou t p atie n t ) a nd hosp italizati on du e  t o 150 d a ys a f te r Dos e  1 for S ea son 1 a nd
RT-PCR- c onf i rm e d RSV, c omp a r e d t o S ea son 2
paliv iz um a b
ADA = a n ti -drug a n ti body ;  AUC = a r ea  und e r t h e  c on ce n t r ati on- ti m e  c urv e;  C max  = m a x i mum obs e rv e d
conce n t r ati on ;  IM = i n t r a mus c u la r ;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  PK = ph a rm ac ok i n etic;  RSV =
respi r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n r eacti on ;  t 1 / 2  = te rm i n al  h al f- li f e .
2.1.[ADDRESS_408874] e n for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t sEndpo i nt
• An ti -RSV n e u t r alizi ng a n ti body le v el s
(IU/mL) i n s e rum for MEDI8897
recip ie n t s c omp a r e d t o p ali v iz um a b
recip ie n t s
• Summ a ry of s e rum RSV n e u t r alizi ng
antibody le v el s (m a y i n cl ud e  GMT,
GMFR, C max , a pp a r e n t  clea r a n ce , a nd t 1 / 2 )
• An ti body le v el s t o RSV F, G a , Gb, or N
at diff e r e n t  ti m e  po i n t s
• Ch a ng e s i n RSV a n ti body le v el s
(seror e spons e ) i nd icati ng e xposur e  t o
RSV
• RSV a n ti g e n a n ti body le v el s (AbU / mL)
to mu lti p le  RSV a n ti g e ns
• Summ a ry of s e rum RSV a n ti body le v el s
(may i n cl ud e  GMT, GMFR,
seroc onv e rs i on r ate s, a pp a r e n t  clea r a n ce ,
and t 1 / 2 )
• M a gn it ud e  of HRU ( e g, numb e r of
admi ss i ons t o hosp ital s a nd ICUs a nd
durati on of s ta y ;  numb e r of sub ject s who
requi r e  r e sp i r at ory suppor t  a nd
supple m e n tal  oxyg e n a nd t h e  dur ati on of
use; numb e r a nd t yp e  of ou t p atie n t  v i s it s
[eg, ER, urg e n t  ca r e , ou t p atie n t  cli n ic ] ;
and numb e r of pr e s c r i p ti on a nd OTC
medicati ons a nd dur ati on of us e ) for
MEDI8897 r eci p ie n t s c omp a r e d t o
paliv iz um a b r eci p ie n t s
• Ca r e g i v e r burd e n ( e g, ca r e g i v e r m i ss e d
work d a ys, sub ject  a bs e n ce  from d a y
care) for sub ject s w it h m e d icall y atte nd e d
LRTI ca us e d by [CONTACT_937]-PCR- c onf i rm e d RSV
CONFIDENTIAL AND PROPRIETARY 23 of 80 T e mp late  18.0
RSV r e s i s ta n ce
monit or i ngMedImmun e
MEDI8897
Table 3Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Exploratory O bj ective s  a nd  E ndp oi n t s
Type Obj ec t i v e Endpo i nt
To ch a r acte r ize  r e s i s ta n ce  t o MEDI8897 G e no t yp ic  a n al ys i s a nd sus ce p ti b ilit y of
and p ali v iz um a b t hrough g e no t yp ic  a nd RSV v a r ia n t s t o n e u t r alizati on by
[CONTACT_330851] t yp ic  a n al ys e s MEDI8897 a nd p ali v iz um a b
To ass e ss t h e  i n ci d e n ce  of m e d icall y In ci d e n ce  of m e d icall y atte nd e d LRTI
RSV LRTI a f te r atte nd e d LRTI du e  t o RT-PCR- c onf i rm e d ( i np atie n t  a nd ou t p atie n t ) du e  t o RT-PCR-
Day 151 RSV, c omp a r e d t o p ali v iz um a b a f te r c onf i rm e d RSV from D a y 152 t o D a y 361
Day 151 for S ea son 1 a nd S ea son 2
AbU / mL = a n ti body un it  p e r mL ;  C max  = m a x i mum obs e rv e d c on ce n t r ati on ;  ER = e m e rg e n c y room ;  GMFR =
geom et r ic  m ea n fo l d-r i s e;  GMT = g e om et r ic  m ea n tite r ;  HRU = h ealt h ca r e  r e sour ce  u tilizati on ;  ICU = i n te ns i v e
care un it;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  OTC = ov e r- t h e - c oun te r ;  RSV = r e sp i r at ory syn c y tial  v i rus ;
RT-PCR = r e v e rs e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n r eacti on ;  t 1 / 2  = te rm i n al  h al f- li f e .
3 STUDY  DESIGN
3.1 Description  of  the  Study
3.1.1 Overv i ew
Study D5290C00005 ( M EDLEY) i s  a pi[INVESTIGATOR_22735] P ha s e 2/3 randomized, double-blind,
palivizumab-controlled s tudy to evaluate the s afety, P K, ADA re s pon s e, and de s criptive
efficacy for M EDI8897 in high-ri sk  infant s  eligible to receive palivizumab when enterin g
their fir s t or s econd R S V s ea s on ( S ea s on 1 or S ea s on 2, re s pectively). Approximately
900 palivizumab-eligible infant s  entering their fir s t R S V s ea s on will be enrolled into one o f
2 cohorts ( F igure 1 ): (1) preterm cohort, including approximately 600 preterm infant s
(≤ 35 week s  GA) without CLD/CH D , or (2) CLD/CHD cohort, including approximately
300 infant s  with CLD of prematurity or hemodynamically s ignificant CHD. A s  minimum o f
100 infant s  with hemodynamically s ignificant CHD will be enrolled. Within each cohort,
randomization will be s tratified by [CONTACT_330852] s phere (northern, s outhern) and s ubject age at the time
of Sea s on 1 randomization ( ≤ 3 mo n th s , > 3 to ≤ 6 month s , > 6 month s ).
Seas o n  1 , Preterm a nd  CLD/CHD Co h ort s
All s ubject s  will be randomized 2:1 to either the M EDI8897 group (approximately
[ADDRESS_408875] s  in the CLD/CHD cohort) or palivizumab group (approximately [ADDRESS_408876] s  in the preterm cohort and approximately 100 s ubjects in
the CLD/CHD cohort). S ubject s  in the M EDI8897 group will receive a s ingle fixed I M  dose
of M EDI8897 followed by 4 once-monthly I M  do s e s  of placebo. The M EDI8897 do s e level
will be s tratified by [CONTACT_50759], ie ,  50 mg for infant s  weighing < 5 kg or 100 mg for infants
weighing ≥ [ADDRESS_408877] s  in the palivizumab group will receive 5 once-monthly I M  do s es o f
15 mg/kg palivizumab.
CONFIDENTIAL AND PROPRIETARY 24 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Seas o n  2 , CLD/CHD Co h ort O n ly
 S ubject s  with CLD/CHD ≤ 24 month s  of age who were randomized to the M EDI8897
group for S ea s on 1 will receive a s ingle fixed I M  do s e of 200 mg M EDI8897 followed by
4 once-monthly I M  do s e s  of placebo (approximately [ADDRESS_408878] s ).
 S ubject s  with CLD/CHD ≤ 24 month s  of age who were randomized to the palivizumab
group for S ea s on 1 will be re-randomized 1:[ADDRESS_408879] s  in the M EDI8897 group will receive a s ingle fixed I M  dose
of 200 mg M EDI8897 followed by 4 once-monthly I M  do s e s  of placebo (approximately
[ADDRESS_408880] s ). S ubject s  in the palivizumab group will receive 5 once-monthly I M  do s es o f
15 mg/kg palivizumab (approximately [ADDRESS_408881] s ).
In Sea s o n  [ADDRESS_408882] s  in the CLD/CHD cohort who undergo cardiac s urgery with
cardiopulmonary by[CONTACT_330853] s e [ADDRESS_408883] s  in the preterm cohort will b e followed through 1 year after S ea s on 1/Do s e 1, and
subject s  in the CLD/CHD cohort will be followed through 1 year after S ea s on 2/Do s e 1.
Subject s  in the CLD/CHD cohort w ho receive a replacement do s e in S ea s on [ADDRESS_408884] s  in the CLD/CHD cohort with a weight < [ADDRESS_408885] increa s ed monitoring of adver s e event s  (AE s ). Any S AE s  or Grade [ADDRESS_408886] s  will be monitored throughout the s tudy for LRTI ( s ee S ection 4.3.1 ). All s ubjects
seeking medical attention for a re s pi[INVESTIGATOR_330808]  (in either the inpatient or outpatient s etting )
will be evaluated for LRTI, including protocol-defined medically attended R S V LRTI
(Table 7 and Table 8 ). All s ubject s  evaluated for LRTI will have re s pi[INVESTIGATOR_696] s ample s  obtained
and te s te d  centrally for R S V u s ing the United S tate s  F ood and Drug Admini s tration
(US F D A )-cleared and Confo r mité Eu r opéenne (CE) or European Conformity-marked in vit r o
diagno s tic real-time rever s e tran s cripta s e-polymera s e chain reaction (RT- P CR) a ss ay ( s ee
Section [IP_ADDRESS] ).
Blood s ample s  will be collected for P K, ADA, and R S V neutralizing antibody and R S V
serology a s  defined in S ection s  4.3.3 , 4.3.4 , and 4.3.5 , re s pectively.
The end p oint s  to be mea s ured in thi s  s tudy are de s cribed in S ection 2.
CONFIDENTIAL AND PROPRIETARY 25 of 80 T e mp late  18.0
MedI mm un e
MEDI8897
Figure 1 Study Flow DiagramProt o c o l  D5290 C [ZIP_CODE] (M E D LE Y) A me nd me n t  1
 31M a r2021 ;  F i n al
ADA  =  anti-drug  antibody;  CHD  =  congenital  heart  disease;  CLD  =  chronic  lung  disease;  IM  =  intramuscular;  PK  =  pharmacokinetic.
SEASON  1:  Randomization  for  Season  1  Day  1,  2:1  MEDI8897  or  palivizumab  group
SEASON  2  (CLD/CHD  cohort  only):  Randomization  for  Season  2  Day  1:  Subjects  who  were  randomized  in  Season  1  to  receive  MEDI8897  will  receive  MEDI8897  in  Season  2.
Subjects  who  were  randomized  to  receive  palivizumab  in  Season  1  will  receive  MEDI8897  or  palivizumab  in  Season  2
Blood  samples  for  PK  and  ADA:  Season  1  for  both  cohorts  –  Screening  or  Day  1  predose  and  on  Days  31  (predose),  151,  and  361  (for  CLD/CHD  cohort,  prior  to  Season  2
dosing);  Season  2  for  CLD/CHD  cohort  only  -  Days  31  (predose),  151,  and  361.  Additionally,  samples  will  be  collected  during  both  seasons  from  all  subjects  hospi[INVESTIGATOR_311291]  a
respi[INVESTIGATOR_23739],  and  before  and  after  cardiac  surgery  with  cardiopulmonary  by[CONTACT_330854]  a  replacement  dose  of  study  drug.
Safety  assessments  will  be  performed  through  Day  361  for  each  respective  season.
a In  the  MEDI8897  group  Season  1,  dose  level  will  be  stratified  by  [CONTACT_330855];  subjects  will  receive  50  mg  MEDI8897  if  <  5  kg  or  100  mg  MEDI8897  if
≥ 5 kg.
CONFID E N T IA L  AND P R OP R I ET A R Y 26 of 80 Tem p late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
3.1.[ADDRESS_408887] s  will be randomly a ss igned to receive s tudy drug a s  outlined in F igure 1 .
[IP_ADDRESS] S ea s o n  1, Preterm Cohort a nd  CLD/CHD Co h ort
In Sea s on 1, s ubject s  in the preterm cohort and CLD/CHD cohort will receive either
MEDI88 9 7 or palivizumab a s  pre s ented in F igure 2 . S ection [IP_ADDRESS] provide s  detail s  on
replacement do s ing for s ubject s  in the CLD/CHD cohort who undergo cardiac s urgery with
cardiopulmonary by[CONTACT_330843]  s urgery.
Figu re 2 Do s i n g Regime n : S ea s o n  1 – Preterm Co h ort a nd  CLD/CHD Co h or t
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  IM = i n t r a mus c u la r.
a V i s it  1 / S c r ee n i ng a nd V i s it  2 / D a y 1 a nd ca n o cc ur on t h e  s a m e  d a y.
b B a s e d on body w ei gh t  at  ti m e  of dos i ng.
[IP_ADDRESS] S ea s o n  2, CLD/CHD Co h ort
In Sea s o n  2, s ubject s  in the CLD/C H D cohort only will receive either M EDI8897 or
palivizumab ba s ed on their randomized do s ing group in S ea s on 1. F igure [ADDRESS_408888] s  who were randomized to receive palivizumab in
Season 1. S ection [IP_ADDRESS] provide s  detail s  on replacement do s ing for s ubject s  in the
CLD/CHD cohort who undergo cardiac s urgery with cardiopulmonary by[CONTACT_330843]  s urgery.
CONFIDENTIAL AND PROPRIETARY 27 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Figu re 3Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Dosi n g Regime n:  S ea s o n  2 – CLD/CHD Co h ort, MED I 8897 Gro up  i n
Seas o n  1
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  IM = i n t r a mus c u la r.
Figu re 4 Do s i n g Regime n:  S ea s o n  2 – CLD/CHD Co h ort, Paliviz u ma b  Grou p  i n
Seas o n  1
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  IM = i n t r a mus c u la r.
a B a s e d on body w ei gh t  at  ti m e  of dos i ng.
[IP_ADDRESS] S ea s o n  1 or S ea s o n  2, CLD/CHD Co h ort - Re p laceme n t Do s e
Subject s  in the CLD/CHD cohort w ho undergo cardiac s urgery with cardiopulmonary by p ass
after receipt of Do s e [ADDRESS_408889] u g that they received for Do s e 1 immediately following the s urgery when determined
by [CONTACT_330856] s ician to be medically s table for an I M  injection. Any s ub s equent do s e s  of s tu d y
drug will continue to be given according to the protocol- s pecified do s ing s chedule. In s ubjects
requiring multiple s urgerie s  during the s ame s ea s on, the do s ing and timing s cheme de s cribed
below s hould be followed relative to the mo s t recent replacement do s e.
CONFIDENTIAL AND PROPRIETARY 28 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Detail s  for the replacement do s e by [CONTACT_330857] s ented below.
MED I 8897 Gro up
S eason 1
 Subject s  undergoing s urge r y < 90 day s  po s t fir s t do s e who originally received 5 0  mg
MEDI8897 will receive a single 50-mg M EDI8897 I M  replacement do s e if < 5 kg
body weight at time of replacement do s ing or a s ingle 100-mg M EDI8897 I M
replacement do s e if ≥ 5 kg body weight at time of replacement do s ing.
Subject s  undergoing s urgery < 90 day s  po s t fir s t do s e who originally received
100 mg M EDI8897 will receive a s ingle 100-mg M EDI8897 I M  replacement dose.
 Subject s  undergoing s urge r y ≥ 90 day s  po s t fir s t do s e who originally received eithe r
50 mg or 100 mg M EDI8897 will receive a s ingle 50-mg M EDI8897 I M  replacement
dose.
S eason 2
Subject s  undergoing s urgery < 90 day s  po s t fir s t do s e will receive a s ingle 200-mg
MEDI8897 I M  replacement do s e.
Subject s  undergoing s urge r y ≥ [ADDRESS_408890] s  will receive a 15 mg/kg palivizumab I M  replacement do s e. Thereafter, do s e s  s hould
be given according to the protocol-specified do s ing s chedule.
3.2 Rationale  for  Dose,  Population,  and  Endpoints
3.2.1 Dose  Rat i ona l e
A single fixed 50-mg I M  do s e wa s  s hown to be efficaciou s  in the P ha s e 2b S tudy
D5290C00003 in preterm infant s  (29 to < 35 week s  GA) in their fir s t R S V s ea s on.
Model-ba s ed analy s e s  of the P ha s e 2b clinical P K and efficacy data identified a projected
serum AUC 0 - ∞  of a s  the protective expo s ure thre s hold. The ri s k of medically
attended R S V-confirmed LRTI over the cour s e of the R S V s ea s on wa s  s ignificantly lowe r  in
infant s  w ith higher projected AUC 0 - ∞ . Infant s  with AUC 0- ∞  above had a
statis tically s ignificantly higher pro b ability of protection ba s ed on expo s ure-re s pon s e analysis
using Cox proportional hazard regre ss ion.
Henceforth, ba s ed on
these analy s e s , a s tratified fixed do s ing s trategy by [CONTACT_50759] s  will be implemented to
ensure an adequate do s e to maintain M EDI8897 s erum concentration s  above the target A UC
CONFIDENTIAL AND PROPRIETARY 29 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
throughout the R S V s ea s on. Ba s ed on do s e optimization analy s i s  de s igned to maximize the
proporti o n of infant s  with clinicall y  efficaciou s  M EDI8897 s erum expo s ure, a s ingle fixed
50-mg I M  do s e will be admini s tered for infant s  < 5 kg in their fir s t R S V s ea s on while a single
fixed 100-mg do s e will be admini s tered for tho s e weighing ≥ 5 kg entering their fir s t R SV
season. Additionally, the body weight range for the P ha s e 2/3 population in the s econd yea r  o f
life at time of do s ing i s  expected to be approximately 8.5 to 15 kg. Therefore, with the s ame
rationale ,  a s ingle fixed 200-mg do s e of M EDI8897 i s  propo s ed for infant s  in the s econd yea r
of life to achieve and maintain efficaciou s  expo s ure during the entire s econd R S V s ea s on.
The appr o ved palivizumab do s ing regimen of 15 mg/kg admini s tered I M  once monthly du r ing
the R S V s ea s on (ie, once monthly for 5 month s ) will be u s ed for thi s  s tudy.
3.2.2 Rat i ona l e  for  Study  Popu l at i on
MEDI8897 ha s  the potential to add r e ss  a s eriou s  unmet medical need by [CONTACT_330858] f ants
from R S V di s ea s e ba s ed on it s  demon s trated increa s ed potency and expected extended
half-life that may s upport once per sea s on do s ing. Becau s e of the s e s ignificant advantages
over palivizumab, including the potential for a s ingle do s e ver s u s  up to 5 monthly do s e s  o f
palivizumab, M EDI8897 may al s o p rovide a s ignificant improvement for prevention of R S V
disea s e in the pediatric population indicated for palivizumab, ie, high-ri s k preterm infant s  and
children up to 2 year s  of age with CLD or CHD. Therefore, thi s  P ha s e 2/[ADDRESS_408891] mea s ure s  of TEAE s /TE S AE s , AE S I s , and NOCD s  will be u s ed f o r
this a ss e ss ment. All s ubject s  will be followed for approximately [ADDRESS_408892] s  with CLD/CHD who receive M EDI8897 for S ea s on [ADDRESS_408893] 5 month s  after do s ing. P alivizumab s erum concentration s  will al s o be evaluated.
MEDI8897 and palivizumab P K data will be s ummarized by [CONTACT_105]-compartmental analy s is.
Additionally, s erum concentration data will be u s ed to characterize the P K of M EDI8897 in
infant s  u s ing a population P K approach s eparately. F or infant s  who require ho s pi[INVESTIGATOR_059] f o r
CONFIDENTIAL AND PROPRIETARY 30 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
LRTI or any re s pi[INVESTIGATOR_4416], an additional s erum s ample for mea s urement of
MEDI8897/palivizumab concentration and ADA will be obtained contemporaneou s  with time
of ho s pi[INVESTIGATOR_059]. Expo s ure-re s ponse analy s i s  will be performed to relate M EDI8897 s e r um
concentration s  and efficacy endpoint s  (LRTI including R S V-a ss ociated ho s pi[INVESTIGATOR_059]).
To determine M EDI8897 and palivizumab s erum level s  po s t do s ing and to correlate wit h  the
potential development of ADA, s erum concentration s  will be mea s ured up to [ADDRESS_408894]
Dose 1 (when M EDI8897 would be given) for both S ea s on 1 and, a s  applicable, S ea s on 2.
ADA to M EDI8897 and to palivizumab will be mea s ured at s elected time point s  through o ut
the stud y  and up to 360 day s  po s t D o s e 1 for each s ea s on a s  well.
This s tu d y will al s o s ummarize efficacy of M EDI8897 and palivizumab in term s  of incidence
of RS V LRTI. Re s pi[INVESTIGATOR_696] s yncytial viru s  re s ult s  in a s ignificant burden of di s ea s e con s isting
of ho s pi[INVESTIGATOR_059], vi s it s  to the eme r gency room (ER), and vi s it s  to outpatient clinic s . This
endpoint i s  de s igned to allow the capture of thi s  total burden of di s ea s e. A s eparate endpoint
of RS V ho s pi[INVESTIGATOR_330809] s o be evaluated. Becau s e of the reduced incidence of R S V
disea s e in thi s  population following the introduction of palivizumab, a s uperiority or
non-inferiority de s ign (with RRR of M EDI8897 over palivizumab a s  the endpoint) i s  not
practical. Thi s  P ha s e 2/3 s tudy i s  de s igned to confirm the s afety and P K while incidence o f
RSV LRTI (and R S V ho s pi[INVESTIGATOR_059]) will be s ummarized and no formal s tati s tical te s t w ill be
conducted. It i s  anticipated that efficacy from the P ha s e 2b and P ha s e 3 s tudie s  in preterm and
term infant s  will be predictive of efficacy in the palivizumab population.
Exploratory endpoint s  will examine magnitude of healthcare re s ource utilization (HRU) and
caregive r  burden due to R S V illne s s in the current population. Thi s  will allow the
determination of s ocial and economic re s ource s  that are required for infant s  who have LRT I .
Serum anti-R S V neutralizing antibody level s  will be evaluated for correlation with s erum
MEDI8897 and palivizumab concentration s . R S V s erology will be evaluated to identify
potential expo s ure to R S V. To monitor for R S V re s i s tance, the F  protein from collected R S V
isolate s  w ill be genetically characterized and novel variant s  will be phenotypi[INVESTIGATOR_330810] r ized for M EDI8897 and palivizumab s u s ceptibility. The incidence of medically
attended LRTI (inpatient and outpatient) due to RT- P CR-confirmed R S V from Day [ADDRESS_408895] s  will be enrolled and randomized to either the
MEDI8897 group (approximately [ADDRESS_408896] s  in the
CONFIDENTIAL AND PROPRIETARY 31 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
preterm cohort and approximately [ADDRESS_408897] s  in the CLD/CHD cohort) or palivizumab
group (approximately [ADDRESS_408898] s  in the CLD/CHD cohort).
4.1.[ADDRESS_408899] s  mu s t meet all of the follo w ing criteria:
1F or the preterm cohort (excluding s ubject s  with CLD or hemodynamically s ignifica n t
CHD ): preterm infant s  in their f ir s t year of life and born ≤ 35 week s  0 day s  GA eligible to
receive palivizumab in accordance with national or local guideline s , including tho s e with:
(a) U ncomplicated s mall atrial or ventricular s eptal defect s  or patent ductu s  arterio s us, or
(b) A ortic s teno s i s , pulmonic s teno s i s , or coarctation of the aorta alone
2F or the CLD/CHD cohort:
(a) Subject s  with CLD - infant s  in their fir s t year of life and a diagno s i s  of CLD of
prematurity requiring medical intervention/management (ie, s upplemental oxygen,
bronchodilator s , or diuretic s ) within the 6 month s  prior to randomization
(b) Subject s  with CHD - infant s  in their fir s t year of life and documented,
hemodynamically s ignificant CHD (mu s t be unoperated or partially corrected C H D )
Note : Infant s  with hemod y namically s ignificant acyanotic cardiac le s ion s  mu s t have
pulmonary hyperten s ion (≥ 40 mmHg mea s ured pre ss ure in the pulmonary artery )  o r
the need for daily medicati o n to manage CHD
3Infant s  who are entering their fir s t R S V s ea s on at the time of s creening
4Written informed con s ent and any locally required authorization (eg, Health In s urance
Portability and Accountability A ct in the U S A, EU Data P rivacy Directive in the E U)
obtained from the s ubject' s  parent( s )/legal repre s entative( s ) prior to performing any
protocol-related procedure s , including s creening evaluation s
5S ubject' s  parent( s )/legal repre s entative( s ) able to under s tand and comply with the
requirement s  of the protocol including follow-up and illne ss  vi s it s  a s  judged by [CONTACT_31035]
[ADDRESS_408900] i s  available to complete the follow-up period, which will be 1 year after S ea s on 1/
Dose [ADDRESS_408901] s  without CLD/CHD, or 1 year after S ea s on 2/Do s e 1 (or la s t
replacement do s e a s  applicable for CHD) for s ubject s  with CLD/CHD
4.1.[ADDRESS_408902] from participation in the s tudy:
1Any fever ( ≥ 100.4° F  [≥ 38.0°C], regardle ss  of route) or acute illne ss  within 7 day s  p r io r
to randomization
2Any hi s tory of LRTI or active LRTI prior to, or at the time of, randomization
3Kno w n hi s tory of R S V infecti o n or active R S V infection prior to, or at the time of,
randomization
CONFIDENTIAL AND PROPRIETARY 32 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4Ho sp italization at the time of randomization, unle ss  di s charge i s  expected within the
7 days  after randomization
5Req u irement for mechanical ventilation, extracorporeal membrane oxygenation, C PAP ,
or other mechanical re s pi[INVESTIGATOR_13521] y  or cardiac s upport at the time of randomization
6Anticipated cardiac s urgery within 2 week s  after randomization
7Anticipated s urvival of < [ADDRESS_408903]
12 Chr o nic s eizure, or evolving or un s table neurologic di s order
13 P rio r  hi s tory of a s u s pected or actual acute life-threatening event
14 Known immunodeficiency, including human immunodeficiency viru s  (HIV)
15 M other with HIV infection (unle ss  the child ha s  been proven to be not infected)
[ADDRESS_408904] s , or hi s tory of allergic reaction
17 Receipt of palivizumab or othe r  R S V mAb or any R S V vaccine, including maternal R S V
vaccination
18 Receipt of any monoclonal or p olyclonal antibody (for example, hepatiti s  B immune
globu lin, intravenou s  immunoglobulin) or anticipated u s e during the s tudy
[ADDRESS_408905]  Enro ll ment  and  Random i zat i on
Study participation begin s  (ie, a s u b ject i s  “enrolled”) once written informed con s ent i s
obtained. Once informed con s ent i s  obtained, a s ubject identification ( S ID) number will be
assigned by a central s y s tem (eg, an interactive web re s pon s e s y s tem [IWR S ]), and the
screening evaluation s  may begin to a ss e ss  s tudy eligibility (inclu s ion/exclu s ion) criteria. The
SID number will be u s ed to identify the s ubject during the s creening proce ss  and throug h out
study participation, if applicable.
A ma s te r  log of all con s ented s ubject s  will be maintained at the s ite and will document all
screenin g  failure s  (ie, s ubject s  who are con s ented but do not meet s tudy eligibility criteria
and/or are not randomized), including the rea s on( s ) for s creening failure.
CONFIDENTIAL AND PROPRIETARY 33 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Subject s  who fail to meet the inclu s ion/exclu s ion criteria (ie, s creening failure s ) s hould not be
randomized or admini s tered s tudy drug. The inve s tigator mu s t con s ult with the s pon s or be f o r e
a subject who ha s  failed s creening may be con s idered for re s creening.
4.1.[ADDRESS_408906] s  may at any time be withdrawn from the s tudy without prejudice to further treatment
(withdrawal of con s ent). The caregiver s  of s uch s ubject s  will alway s  be a s ked about the
reason( s ) for withdrawal and the pre s ence of any AE s . If po ss ible, the s ubject will be s ee n  and
assess ed by [CONTACT_132366] s tigator. AE s  w ill be followed up. If a s ubject withdraw s  from furthe r
participation in the s tudy, then no further s tudy vi s it s  or data collection s hould take place.
4.1.[ADDRESS_408907] s  with CLD/CHD, if any of the following occur in the s ubject in
question:
1Withdrawal of con s ent
2Hyper s en s itivity reaction a ss e s sed a s  related to s tudy drug
Subject s  who have received any s tudy drug will be followed for protocol- s pecified
assess ment s  including follow-up of any AE s  unle ss  con s ent i s  withdrawn s pecifically from
further s tudy participation ( S ection 4.1.5 ) or the s ubject i s  lo s t to follow-up. S ubject s  wh o
have not received s tudy drug, regardle ss  of rea s on, will not be followed.
4.1.[ADDRESS_408908] withdraw s  con s ent to the u s e of donated biological s ample s , the s ample s  will be
dispo s ed of/de s troyed, and the acti o n documented. If s ample s  are already analyzed,
MedImmune i s  not obliged to de s troy the re s ult s  of thi s  re s earch.
The P rincipal Inve s tigator:
 En s ure s  s ubject s ’ withdrawal of informed con s ent to the u s e of donated s ample s  i s
notified immediately to M edImmune.
 En s ure s  that biological s ample s  from that s ubject, if s tored at the s tudy s ite, are
immediately identified, di s po s ed of/de s troyed, and the action documented.
CONFIDENTIAL AND PROPRIETARY 34 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
En su re s  the organization( s ) holding the s ample s  i s /are informed about the withdrawn
consent immediately and that s ample s  are di s po s ed of/de s troyed, the action documented,
and the s igned document returned to the s tudy s ite.
En s ure s  that the s ubject and M edImmune are informed about the s ample di s po s al.
MedImmune en s ure s  the organization s  holding the s ample s  i s /are informed about the
withdrawn con s ent immediately and that s ample s  are di s po s ed of/de s troyed and the action
docume n ted and returned to the s tudy s ite.
4.2 Schedule  of  Study  Procedures
Whenever vital s ign s  and blood dra ws  are s cheduled for the s ame nominal time, vital s igns
should occur prior to blood draw s .
4.2.1 Enro ll ment / Screen i ng  Per i od
Table 4 show s  all procedure s  to be conducted at the s creening vi s it.
Table 4 S c h e du le of S cree n i n g Proce du re s
Study P eri od
Visit Numb er
Proce du re  /  Study Day
Writte n i nform e d c ons e n t/  a ss i gnm e n t  of SID numb e r
Medical  h i s t ory
Phys ical  e x a m i n ati on
Weigh t
Vital  s i gns
Blood s a mp le  for PK, ADA, RSV n e u t  Ab, a nd RSV s e ro l ogy a
Asse ssm e n t  of AEs / SAEs
Conc om ita n t  m e d icati ons
Verify eli g i b ilit y c r ite r iaScree n i ng
V1
Day -30 to Day 1
 X
 X
 X
 X
 X
X
X
X
X
ADA = a n ti -drug a n ti body ;  AEs = a dv e rs e  e v e n t s ;  n e u t  Ab = n e u t r alizi ng a n ti body ;  PK = ph a rm ac ok i n etic;
RSV = r e sp i r at ory syn c y tial  v i rus ;  SAEs = s e r i ous a dv e rs e  e v e n t s ;  SID = sub ject  i d e n ti f icati on ;  V = v i s it .
Visit  1 / S c r ee n i ng a nd V i s it  2 / D a y 1 v i s it s m a y o cc ur on t h e  s a m e  d a y.
a If V i s it  1 / S c r ee n i ng a nd V i s it  2 / D a y 1 do no t  o cc ur on t h e  s a m e  d a y, b l ood s a mp le  for PK, ADA, RSV
neut Ab, a nd RSV s e ro l ogy ca n b e  c o llecte d at  eit h e r V i s it  1 / S c r ee n i ng or V i s it  2 / D a y 1 pr e dos e .
CONFIDENTIAL AND PROPRIETARY 35 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.2.2 Treatment  and  Fo ll ow-up  Per i ods
All procedure s  to be conducted during the treatment and follow-up period s  are pre s ented in
Table 5 f or S ea s on 1, preterm and CLD/CHD cohort s  and Table 6 for S ea s on 2, CLD/C H D
cohort only.
CONFIDENTIAL AND PROPRIETARY 36 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  1, Pre t er m  a nd  CLD/CHD
Cohort s
Study  Period Treatment  Period Follow-up  Period
Visit  Number V2  a TC V3 V4 V5 V6 V7 V8 V9  b TC LRTISkin
Reaction
Procedure  /
Study  Day
Medical  history
update
Physical
examination
Weight
Vital  signs
Blood  sample  for
PK, ADA,  RSV
neut Ab,  and  RSV
serology  d
Assessment  of
AEs/SAEs,  AESIs,
NOCDs
Concomitant
medications
Verify  eligibility
criteria
Randomization  g
Study  drug
administration  h
Assessment  of  LRTI
or any  respi[INVESTIGATOR_330811]8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
X X X
X X X
X X X
X c X               X  c
X
X e (pre-
dose)
X X X X
X X X X
X
X
X XD61            D91           D121           D151
(± 2            (±  2            (±  2             (±  7
days)          days)          days)          days)
X X X X
X X X X
X               X                X                 X
Xc                 X  c                 X  c                   X
X
X X X X
X X X X
X X XD361 D1-151
(± 7              Q2W
days) (±  5  days)
X
X
X
X
X
X X
X XD152-361
monthly
(± 5 days)
X
XD1-361
as needed
X f
X
X
X f
X fD1-361
as needed
X
X
X i
CONFIDENTIAL AND PROPRIETARY 37 of 80 T e mp late  18.0
XMedImmun e
MEDI8897
Table 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  1, Pre t er m  a nd  CLD/CHD
Cohort s
Study  Period Treatment  Period Follow-up  Period
Visit  Number V2  a TC V3 V4 V5 V6 V7 V8 V9  b TC LRTISkin
Reaction
Procedure  /
Study  Day
Telephone
contact  [CONTACT_330859]8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
XD61            D91           D121           D151
(± 2            (±  2            (±  2             (±  7
days)          days)          days)          days)D361 D1-151
(± 7              Q2W
days) (±  5  days)
XD152-361
monthly
(± 5 days)
XD1-361
as neededD1-361
as needed
HRU  and  caregiver
burden  k
ADA  =  anti-drug  antibody;  AEs  =  adverse  events;  AESIs  =  adverse  events  of  special  interest;  CHD  =  congenital  heart  disease;  CLD  =  chronic  lung  disease;  D  =  study  day;  ER
= emergency  room;  HRU  =  healthcare  resource  utilization;  ICU  =  intensive  care  unit;  IM=intramuscular;  LRTI  =  lower  respi[INVESTIGATOR_330812];  neut  Ab  =  neutralizing
antibody;  NOCDs  =  new  onset  chronic  diseases;  OTC  =  over-the-counter;  PK  =  pharmacokinetic;  Q2W  =  once  every  2  weeks;  RSV  =  respi[INVESTIGATOR_330813];  SAEs  =
serious  adverse  events;  SID  =  subject  identification;  TC  =  telephone  call;  V  =  visit.
a Visit  2/Day  1  and  Visit  1/Screening  can  occur  on  the  same  day.
b For  subjects  in  the  CLD/CHD  cohort,  the  Season  1  Visit  9/Day  361  may  be  the  same  as  the  Season  2  Visit  10/Day  1  (Dose  1).
c  All  vital  signs  (temperature,  blood  pressure,  heart  rate,  and  respi[INVESTIGATOR_2842])  should  be  obtained  within  60  minutes  prior  to  dosing,  and  at  30  minutes  (±  5  minutes)  and
60 minutes  (±  5  minutes)  post  dose.
d Subjects  requiring  a  replacement  dose  of  study  drug  due  to  cardiac  surgery  with  cardiopulmonary  by[CONTACT_330860]  a  blood  sample  collected  before  and  after  surgery
(prior  to  administering  replacement  dose)  for  PK  evaluation.
e If  Visit  1/Screening  and  Visit  2/Day  1  do  not  occur  on  the  same  day,  blood  sample  for  PK,  ADA,  RSV  neut  Ab,  and  RSV  serology  can  be  collected  at  either
Visit  1/Screening  or  Visit  2/Day  1  predose.
f Nasal  samples  will  be  collected  from  all  subjects  with  LRTIs  (inpatient  or  outpatient)  and  from  all  hospi[INVESTIGATOR_330814]  (upper  or
lower)  within  approximately  2  days  after  the  initial  healthcare  provider  assessment  and  diagnosis.
Blood  samples  will  be  collected  from  all  subjects  hospi[INVESTIGATOR_330815]  2  days  following  hospi[INVESTIGATOR_105904].
g Subjects  in  each  cohort  (preterm  and  CLD/CHD  cohorts)  will  be  randomized  2:1  to  receive  either  MEDI8897  administered  as  a  stratified  dose  by  [CONTACT_330861],  which
includes  a  single  fixed  50-mg  IM  dose  for  infants  weighing  <  5  kg  or  100-mg  IM  dose  for  infants  weighing  ≥  5  kg,  followed  by  4  once-monthly  IM  doses  of  placebo;  or
5 once-monthly  IM  doses  of  15  mg/kg  palivizumab.
h Subjects  who  undergo  cardiac  surgery  with  cardiopulmonary  by[CONTACT_330862]  1  but  prior  to  receipt  of  Dose  5  will  receive  a  replacement  dose  of  the  study  drug
that they  received  for  Dose  1  immediately  following  the  surgery  when  determined  by  [CONTACT_330863].  Any  subsequent  doses  of
study  drug  will  continue  to  be  given  according  to  the  protocol-specified  dosing  schedule.  See  Section  [IP_ADDRESS]  for  details.
i Skin  reaction  assessment  will  be  done  for  any  post-dosing  skin  or  skin-related  reaction  regardless  of  severity,  duration,  time  of  onset  post  dosing,  or  relationship  to  study
drug.
CONFIDENTIAL AND PROPRIETARY 38 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  1, Pre t er m  a nd  CLD/CHD
Cohort s
Study  Period Treatment  Period Follow-up  Period
Visit  Number V2  a TC V3 V4 V5 V6 V7 V8 V9  b TC LRTISkin
Reaction
Procedure  /
Study  DayD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)D61            D91           D121           D151
(± 2            (±  2            (±  2             (±  7
days)          days)          days)          days)D361 D1-151
(± 7              Q2W
days) (±  5  days)D152-361
monthly
(± 5 days)D1-[ADDRESS_408909]  be  verbal  communication.  Written  communication  via  text,  email,  or  other  written  form  is  not  acceptable.
k  HRU  includes  admission  and  duration  of  hospi[INVESTIGATOR_330816],  number  of  subjects  who  require  respi[INVESTIGATOR_330817],  duration  of  respi[INVESTIGATOR_330818],  number  and  type  of  outpatient  visits  (eg,  ER,  urgent  care,  outpatient  clinic),  and  number  and  days  of  prescription  and  OTC
medication.  Caregiver  burden  includes  days  of  worked  missed  by  [CONTACT_3040](s)/legal  representative  or  other  household  member  as  a  result  of  the  subject’s  illness,  and  days
of daycare/baby[CONTACT_330864]  a  result  of  illness.
CONFIDENTIAL AND PROPRIETARY 39 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 6Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  2, CLD/CHD Co h or t  O n ly
Study  Period Treatment  Period Follow-up  Period
Visit  Number V10  a TC V11 V12 V13 V14 V15 V16 V17 TC LRTISkin
ReactionReplacement
 Dose
Follow-up  b
Procedure  /
Study  Day
Medical  history
update
Physical
examination
Weight
Vital  signs
Blood  sample  for
PK, ADA,  RSV
neut Ab,  and  RSV
serology  d
Assessment  of
AEs/SAEs,  AESIs,
NOCDs
Concomitant
medications
Randomization  f
Study  drug
administration  gD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
X X X
X X X
X X X
X c X              X c
X
(pre-
dose)
X X X X
X X X X
X
X XD61           D91
(± 2            (±  2
days)         days)
X X
X X
X X
Xc                X c
X X
X X
X XD121        D151
(± 2           (±  7
days)        days)
X X
X X
X             X
Xc                 X
X
X X
X X
XD361 D1-151
(± 7           Q2W
days) (±  5  days)
X
X
X
X
X
X X
X XD152–361      D1-361 D1-361
monthly as                 as
(± 5 days) needed needed
X e
X X X
X X X360  days
post  last
replacement
dose
(± 7 days)
X
X
X
X
X
X
X
CONFIDENTIAL AND PROPRIETARY 40 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 6Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  2, CLD/CHD Co h or t  O n ly
Study  Period Treatment  Period Follow-up  Period
Visit  Number V10  a TC V11 V12 V13 V14 V15 V16 V17 TC LRTISkin
ReactionReplacement
 Dose
Follow-up  b
Procedure  /
Study  Day
Assessment  of  LRTI
or any  respi[INVESTIGATOR_330819]  i
HRU  and  caregiver
burden  jD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)
XD61           D91
(± 2            (±  2
days)         days)D121        D151
(± 2           (±  7
days)        days)D361 D1-151
(± 7           Q2W
days) (±  5  days)
XD152–361      D1-361 D1-361
monthly as                 as
(± 5 days) needed needed
X e
X e
X h
X
X360  days
post  last
replacement
dose
(± 7 days)
ADA  =  anti-drug  antibody;  AEs  =  adverse  events;  AESIs  =  adverse  events  of  special  interest;  CHD  =  congenital  heart  disease;  CLD  =  chronic  lung  disease;  D  =  study  day;
ER =  emergency  room;  HRU  =  healthcare  resource  utilization;  ICU  =  intensive  care  unit;  IM=intramuscular;  LRTI  =  lower  respi[INVESTIGATOR_330812];  neut  Ab  =  neutralizing
antibody;  NOCDs  =  new  onset  chronic  diseases;  OTC  =  over-the-counter;  PK  =  pharmacokinetic;  Q2W  =  once  every  2  weeks;  RSV  =  respi[INVESTIGATOR_330813];  SAEs  =
serious  adverse  events;  SID  =  subject  identification;  TC  =  telephone  call;  V  =  visit.
a The  Season  2  Visit  10/Day  1  (Dose  1)  may  be  the  same  as  the  Season  1  Visit  9/Day  361.
b Subjects  who  receive  a  replacement  dose  of  study  drug  due  to  cardiac  surgery  with  cardiopulmonary  by[CONTACT_330865]  [ADDRESS_408910]  replacement  dose.
c  All  vital  signs  (temperature,  blood  pressure,  heart  rate,  and  respi[INVESTIGATOR_2842])  should  be  obtained  within  60  minutes  prior  to  dosing,  and  at  30  minutes  (±  5  minutes)  and
60 minutes  (±  5  minutes)  post  dose.
CONFIDENTIAL AND PROPRIETARY 41 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 6Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Sche du le of Treatme n t Perio d  a nd  Follow- up  Perio d  S t ud y Proce du res :  S easo n  2, CLD/CHD Co h or t  O n ly
Study  Period Treatment  Period Follow-up  Period
Visit  Number V10  a TC V11 V12 V13 V14 V15 V16 V17 TC LRTISkin
ReactionReplacement
 Dose
Follow-up  b
Procedure  /
Study  DayD8 D15 D31
D1 (±  2 (±  2 (±  2
days) days) days)D61           D91
(± 2            (±  2
days)         days)D121        D151
(± 2           (±  7
days)        days)D361 D1-151
(± 7           Q2W
days) (±  5  days)D152–361      D1-361 D1-361
monthly as                 as
(± 5 days) needed needed360  days
post  last
replacement
dose
(± 7 days)
d  Subjects  requiring  a  replacement  dose  of  study  drug  due  to  cardiac  surgery  with  cardiopulmonary  by[CONTACT_330860]  a  blood  sample  collected  before  and  after  surgery  (prior
to administering  replacement  dose)  for  PK  evaluation.
e  Nasal  samples  will  be  collected  from  all  subjects  with  LRTIs  (inpatient  or  outpatient)  and  from  all  hospi[INVESTIGATOR_330814]  (upper  or  lower)
within  approximately  2  days  after  the  initial  healthcare  provider  assessment  and  diagnosis.
Blood  samples  will  be  collected  from  all  subjects  hospi[INVESTIGATOR_330815]  2  days  following  hospi[INVESTIGATOR_105904].
f Subjects  who  were  randomized  to  receive  MEDI8897  for  Season  1  will  receive  a  single  200-mg  IM  dose  of  MEDI8897  followed  by  4  once-monthly  IM  doses  of  placebo
for Season  2.  Subjects  who  were  randomized  to  receive  palivizumab  for  Season  1  will  be  re-randomized  1:1  to  receive  a  single  200-mg  IM  dose  of  MEDI8897  followed  by
4 once-monthly  IM  doses  of  placebo,  or  5  once-monthly  IM  doses  of  15  mg/kg  palivizumab  for  Season  2.
g  Subjects  who  undergo  cardiac  surgery  with  cardiopulmonary  by[CONTACT_330862]  1  but  prior  to  receipt  of  Dose  5  will  receive  a  replacement  dose  of  the  study  drug
that they  received  for  Dose  1  immediately  following  the  surgery  when  determined  by  [CONTACT_330863].  Any  subsequent  doses  of
study  drug  will  continue  to  be  given  according  to  the  protocol-specified  dosing  schedule.  See  Section  [IP_ADDRESS]  for  details.
h Skin  reaction  assessment  will  be  done  for  any  post-dosing  skin  or  skin-related  reaction  regardless  of  severity,  duration,  time  of  onset  post  dosing,  or  relationship  to  study
drug.
i Telephone  contact  [CONTACT_330866].  Written  communication  via  text,  email,  or  other  written  form  is  not  acceptable.
j  HRU  includes  admission  and  duration  of  hospi[INVESTIGATOR_330816],  number  of  subjects  who  require  respi[INVESTIGATOR_330817],  duration  of  respi[INVESTIGATOR_330818],  number  and  type  of  outpatient  visits  (eg,  ER,  urgent  care,  outpatient  clinic),  and  number  and  days  of  prescription  and  OTC
medication.  Caregiver  burden  includes  days  of  worked  missed  by  [CONTACT_3040](s)/legal  representative  or  other  household  member  as  a  result  of  the  subject’s  illness,  and  days
of daycare/baby[CONTACT_330864]  a  result  of  illness.
CONFIDENTIAL AND PROPRIETARY 42 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.[ADDRESS_408911] s  will be monitored throughout the s tudy for LRTI ( s ee Table 5 and Table 6 ). All
subject s  seeking medical attention f or a re s pi[INVESTIGATOR_330808]  (in either the inpatient or outpatient
setting) w ill be evaluated for LRTI. All s ubject s  found to have an LRTI and all s ubject s  who
require ho s pi[INVESTIGATOR_272] a re s pi[INVESTIGATOR_4416], even if there i s  not a diagno s i s  of LRTI,
should have re s pi[INVESTIGATOR_696] s ample s  obtained and re s pi[INVESTIGATOR_696] a ss e ss ment form s  completed.
Sample s  s hould be collected for all of the s e re s pi[INVESTIGATOR_110636] s  even tho s e not meeting the
protocol definition of LRTI. S ubject s  who have a primary ho s pi[INVESTIGATOR_272] a re s pi[INVESTIGATOR_130229] (ie, upper or lower tract) or a re s pi[INVESTIGATOR_316667] a ho s pi[INVESTIGATOR_059], or
who s eek outpatient medical attenti o n (including ER vi s it s ) for a lower re s pi[INVESTIGATOR_330808] , will
be ass e ss ed clinically for the pre s ence of LRTI and for R S V by [CONTACT_330867] o stic
testing of re s pi[INVESTIGATOR_696] s ecretion s . Te s ting for R S V will be performed u s ing the U S  F DA-cleared
and CE-marked in vitro diagno s tic real-time RT- P CR a ss ay (Lyra R S V + human
metapneumoviru s  [h MP V] a ss ay; Q uidel Corporation, S an Diego, CA, www.quidel.com; see
Section [IP_ADDRESS] ). A diagno s i s  of R SV  LRTI require s  having a re s pi[INVESTIGATOR_696] s ample po s itive f o r
RSV by [CONTACT_330868]- P CR a ss ay.
In addition to the clinical a ss e ss ment of LRTI, there i s  a protocol definition u s ing objective
criteria for the determination of a medically attended protocol-defined LRTI.
For sub ject s  wit h  n o und erlyi n g l un g d i s ea s e:
To meet the protocol-defined endpoint of medically attended R S V LRTI, s ubject s  with s igns
of LRTI mu s t have documented at lea s t one phy s ical examination finding of rhonchi, rales,
crackle s , or wheeze AND at lea s t one of the following clinical s ign s  ( s ee Table 7 ):
Increa s ed re s pi[INVESTIGATOR_316670] (age: < 2 month s , ≥ 60 breath s /min; 2 to 6 month s ,
≥ 50 breath s /min; > 6 month s , ≥ 40 breath s /min), OR
Hypoxemia (in room air: oxygen s aturation < 95% at altitude s  ≤ 1,800 meter s  or < 9 2%  at
altitude s  > 1,800 meter s ), OR
 Clinical s ign s  of s evere re s pi[INVESTIGATOR_193843] s ea s e (eg, acute hypoxic or ventilatory failure, new
onset apnea, na s al flaring, interco s tal, s ubco s tal or s upraclavicular retraction s , grunting )
or dehydration s econdary to inadequate oral intake due to re s pi[INVESTIGATOR_193843] s tre ss  (need fo r
intravenou s  fluid).
CONFIDENTIAL AND PROPRIETARY 43 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 7Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Criteria for Meeti n g t h e Protocol- d efi n e d  E ndp oi n t of Me d ically
Attend e d  R S V LRT I  - Sub ject s  Wit h o u t U nd erlyi n g L un g Di s ea s e
RSV
RSV Conf ir m e d :Lower  R e sp ir ato r y T r a c t
Docum e nt e d phys ic a lMed ic a l  S i gn i f ic an ce
Objec t i v e  m e asu re s of cli n ic a l  s e v eri ty :
•Pos iti v e  by [INVESTIGATOR_6125] n t r al
labor at ory r eal - ti m e
RT-PCR a ss a yexam i nat i on f i nd i ngs l o c a lizi ng
to low er  re sp ir ato r y t r a c t :
•Rhon c h i
•R ale s
•Cr ac k le s
•Wh eeze•In c r ea s e d r e sp i r at ory r ate
•Hypox e m ia
•A c u te  hypox ic  or v e n tilat ory f ail ur e
•N e w ons et  a pn ea
•N a s al  f la r i ng
•R et r acti ons
•Grun ti ng
• D e hydr ati on du e  t o r e sp i r at ory
distre ss
LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  RSV = r e sp i r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -
polym e r a s e  c h ai n r eacti on.
Note:  On e  ite m from eac h c o l umn i s r e qu i r e d t o m eet  t h e  pro t o c o l -d e f i n e d e ndpo i n t  of m e d icall y atte nd e d
RSV LRTI.
For subj ect s  wit h  und erlyi n g l un g d i s ea s e (CLD or CHD):
To meet the protocol-defined endpoint of medically attended R S V LRTI, s ubject s  with s igns
of LRTI mu s t have documented at lea s t one new or wor s ened phy s ical examination finding o f
rhonchi, rale s , crackle s , or wheeze A ND at lea s t one of the following clinical s ign s  ( s ee
Table 8 ):
 Increa s e in ba s eline re s pi[INVESTIGATOR_172675] ≥ 20% at re s t and that rate i s  greater than the
age-ba s ed criteria e s tabli s hed f o r children with no underlying lung di s ea s e
(age: < 2 month s , ≥ 60 breath s /min; 2 to 6 month s , ≥ 50 breath s /min; > 6 month s ,
≥ 40 breath s /min), OR
Hypoxemia (O 2  s aturation < 95% in room air or O 2  s aturation drop of 5 percentage p oints
from ba s eline in children with ba s eline O 2  s aturation < 95% in room air, or acute
docu mented need for s upplemental O 2  or increa s ed O 2  requirement compared with
baseline), OR
Clinical s ign s  of s evere re s pi[INVESTIGATOR_193843] s ea s e (eg, acute hypoxic or ventilatory failure, new
onset apnea, na s al flaring, interco s tal, s ubco s tal or s upraclavicular retraction s , grunting )
or dehydration s econdary to inadequate oral intake due to re s pi[INVESTIGATOR_193843] s tre ss  (need fo r
intravenou s  fluid), OR
 P re s cription of new or increa s ed (from ba s eline) do s e of medication s  including
bronchodilator s , s teroid s , diuretic s , cardiac medication s
CONFIDENTIAL AND PROPRIETARY 44 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 8Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Criteria for Meeti n g t h e Protocol- d efi n e d  E ndp oi n t of Me d ically
Attend e d  R S V LRT I  – Sub ject s  Wit h  U nd erlyi n g L un g Di s ea s e (CLD
or CHD)
RSV
RSV Conf ir m e d :Lower  R e sp ir ato r y T r a c t
Docum e nt e d n e w o r  wo r s e n e dMed ic a l  S i gn i f ic an ce
Objec t i v e  m e asu re s of cli n ic a l  s e v eri ty :
•Pos iti v e  by [INVESTIGATOR_6125] n t r al
labor at ory r eal - ti m e
RT-PCR a ss a yphys ic a l  e xam i nat i on f i nd i ngs
localizi ng to l ow er  re sp ir ato r y
tract :•In c r ea s e d r e sp i r at ory r ate  (from
baseli n e )
•Hypox e m ia
•Rhon c h i
•R ale s
•Cr ac k le s
•Wh eeze•A c u te  hypox ic  or v e n tilat ory f ail ur e
•N e w ons et  a pn ea
•N a s al  f la r i ng
•R et r acti ons
•Grun ti ng
• D e hydr ati on du e  t o r e sp i r at ory
distre ss
•Pr e s c r i p ti on of n e w or i n c r ea s e d
(from b a s eli n e ) dos e  of m e d icati ons
includ i ng bron c hod ilat ors, s te ro i ds,
diuretic s, ca rd iac  m e d icati on
CHD = c ong e n ital  h ea r t  d i s ea s e;  CLD = c hron ic  l ung d i s ea s e;  LRTI = l ow e r r e sp i r at ory t r act  i nf ecti on ;  PE =
physical  e x a m i n ati on ;  RSV = r e sp i r at ory syn c y tial  v i rus ;  RT-PCR = r e v e rs e  t r a ns c r i p ta s e -po l ym e r a s e  c h ai n
reacti on.
Note:  On e  ite m from eac h c o l umn i s r e qu i r e d t o m eet  t h e  pro t o c o l -d e f i n e d e ndpo i n t  of m e d icall y atte nd e d
RSV LRTI.
RSV Ho s pit a liz a tion
An R S V ho s pi[INVESTIGATOR_059] i s  defined a s  either (1) a re s pi[INVESTIGATOR_330820] s pi[INVESTIGATOR_18506] a po s iti v e
RSV te s t within approximately 2 day s  of ho s pi[INVESTIGATOR_330804] (primary) or (2) a new on s et o f
respi[INVESTIGATOR_141876] r y s ymptom s  in an already ho s pi[INVESTIGATOR_057] s ubject, with an objective mea s ure of
wors ening re s pi[INVESTIGATOR_696] s tatu s  and positive R S V te s t (no s ocomial). P rimary and no s ocomial
RSV hospi[INVESTIGATOR_316705].
Primary R S V Ho sp italizatio n
RSV diagno s tic te s ting will be perf o rmed on re s pi[INVESTIGATOR_696] s ecretion s  obtained within
approximately [ADDRESS_408912] s  ho s pi[INVESTIGATOR_330821] s pi[INVESTIGATOR_141876] r y
infection (upper or lower re s pi[INVESTIGATOR_4352]). If the R S V diagno s tic te s t (performed centrally via
RT-P CR) i s  po s itive, the ho s pi[INVESTIGATOR_330822] a s  a primary R S V ho s pi[INVESTIGATOR_059].
Death s  that can be demon s trated a s  cau s ed by R S V (by [CONTACT_330869] s y or clinical hi s tory and
virologic evidence) will al s o be con s idered a s  primary R S V ho s pi[INVESTIGATOR_330823] s .
CONFIDENTIAL AND PROPRIETARY 45 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Nosocomial R S V Ho sp italizatio n
Subject s  ho s pi[INVESTIGATOR_80529] a re s pi[INVESTIGATOR_330824]-re s pi[INVESTIGATOR_330825] s e R S V diagnostic
test i s  negative may develop no s ocomial R S V illne ss  during the s tudy.
If sign s  ( s uch a s  retraction s , rhonchi, wheezing, crackle s  or rale s ) of a new lower re s pi[INVESTIGATOR_141876] r y
illness  occur during a ho s pi[INVESTIGATOR_5186] n , whatever the rea s on for ho s pi[INVESTIGATOR_059], and there i s  an
objective mea s ure of wor s ening re s pi[INVESTIGATOR_696] s tatu s  (that i s , new requirement for s upplemental
oxygen, increa s e in s upplemental oxygen requirement from prior to the on s et of s ymptoms, o r
need for new or additional mechanical ventilation), a s pecimen will be collected within
approximately [ADDRESS_408913] who i s  ho s pi[INVESTIGATOR_80529] a re s pi[INVESTIGATOR_4416] (upper o r
lower re s pi[INVESTIGATOR_4352]), the s ubject mu s t return to hi s /her ba s eline re s pi[INVESTIGATOR_696] s tatu s  or be
clearly re s olving the preceding re s pi[INVESTIGATOR_330826] a s ub s equent re s pi[INVESTIGATOR_330827] r ation
for a no s ocomial R S V ho s pi[INVESTIGATOR_1314] o n event can be determined.
If the R S V diagno s tic te s t (performed centrally via RT- P CR) i s  po s itive, the s ub s equent
hospi[INVESTIGATOR_19156] s  will count a s  a no s ocomial R S V ho s pi[INVESTIGATOR_059]. The day s  of R S V
hospi[INVESTIGATOR_330828] s tart of the re s pi[INVESTIGATOR_330829] R S V diagno s tic te s t.
RSV LRTI Outp a ti e nt E ve nt s
Subject s  who s eek outpatient medical attention, including ER and urgent care vi s it s , for an
LRTI s hould have re s pi[INVESTIGATOR_696] s ecretion s  obtained within approximately 2 day s  after the initial
healthcare provider a ss e ss ment.
[IP_ADDRESS] Re sp iratory S ecretio n s for R S V Detectio n
Respi[INVESTIGATOR_696] s ecretion s  for R S V te s ting mu s t be collected from all s ubject s  with LRTI s
(inpatient or outpatient) and from all ho s pi[INVESTIGATOR_057] s ubject s  with any new re s pi[INVESTIGATOR_4416]
(upper or lower) within approximately [ADDRESS_408914] i s  intubated, and then
tracheal secretion s  may be obtaine d .
Respi[INVESTIGATOR_696] s ecretion s  will be te s ted in a central laboratory for R S V u s ing the U S  F DA-
cleared and CE-marked in vitro dia g no s tic real-time RT- P CR a ss ay (Lyra R S V + h MP V
assay; Quidel Corporation, S an Diego, CA, www.quidel.com). Te s ting may include othe r
respi[INVESTIGATOR_141876] r y pathogen s .
[IP_ADDRESS] Mo n itori n g for R S V R e s i s ta n ce
As an exploratory endpoint, novel R S V F  variant s  identified in R S V-po s itive na s al s pecimens
(based o n  the R S V diagno s tic te s t re s ult s ; S ection [IP_ADDRESS] ) from all s ubject s  will be evaluated
CONFIDENTIAL AND PROPRIETARY 46 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
by [CONTACT_330870] s  to monitor potential s u s ceptibility change s  to
MEDI8897 and palivizumab neutralization. The s ubtype and genotypic determination of R S V
will be performed directly on the na s al s pecimen s  that are collected from all s ubject s  who a r e
confirmed R S V-po s itive u s ing the Lyra R S V + h MP V real-time RT- P CR a ss ay manufactu r ed
by [CONTACT_330871] (Lyra R S V + h MP V a ss ay; Quidel Corporation, S an Diego CA,
www.quidel.com). The full-length F gene will be amplified u s ing a s tandard, s ingle-tube
population-ba s ed RT- P CR method and s equenced by S anger s equencing methodology. A mino
acid s ubstitution( s ) within the M EDI8897 binding s ite (amino acid [aa] 62-69 and aa 196 - 212 )
and out s ide the binding s ite in the extracellular region s  of mature F  protein (aa 24-109 and
aa 137-524) will be reported and compared to F  protein s equence s  of contemporary reference
RSV s train s . In vitro phenotypic analy s i s  ( s u s ceptibility to M EDI8897 and palivizumab
neutralization) will be attempted u s ing an R S V neutralization a ss ay with either R S V vir u ses
constructed through s ite-directed m u tagene s i s  of the F  gene and rever s e genetic s  or by [INVESTIGATOR_243750] o ning
the F  ge n e from the i s olate into a laboratory-adapted R S V s train s uch a s  A2 or B9320.
4.3.2 Med i ca l H i story  and  Phys i ca l Exam i nat i on,  We i ght,  and  V i ta l S i gns
A complete medical hi s tory will be obtained at s creening and a medical hi s tory update will be
obtained during the treatment and follow-up period a s  defined in S ection 4.2. A ss e ss ment will
include hi s tory and current medical condition s , pa s t or pre s ent cardiova s cular di s order s ,
respi[INVESTIGATOR_141876] r y, ga s trointe s tinal, renal, h epatic, neurological, endocrine, lymphatic, hematologic,
immunologic, dermatological, genitourinary, drug and s urgical hi s tory, or any other di s eases
or dis order s .
A phy s ical examination, including w eight, will be performed at s creening and during the
treatment and follow-up period a s  defined in S ection 4.2.
Vital s ign s  (temperature, blood pre ss ure, heart rate, and re s pi[INVESTIGATOR_697]) will be collected at
screening and during the treatment and follow-up period a s  defined in S ection 4.2. On days
when s tudy drug i s  admini s tered, vital s ign s  will be obtained within 60 minute s  prior to
dosing, and at 30 minute s  (± 5 minute s ) and 60 minute s  (± 5 minute s ) po s t do s e.
Baseline information will be collected on brea s tfeeding, s moking in the hou s ehold, and i f  the
infant attend s  day care.
4.3.[ADDRESS_408915] information,
specific to thi s  clinical re s earch s tudy.
Blood s ample s  will be collected to evaluate P K of M EDI8897 and palivizumab in s erum ( see
Section 4 .2.2 for collection time point s ). S ubject s  in the CLD/CHD cohort requiring a
CONFIDENTIAL AND PROPRIETARY 47 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
replacement do s e of s tudy drug due to cardiac s urgery with cardiopulmonary by[CONTACT_330872]
a blood sample collected before and after s urgery (prior to admini s tering replacement dose )  to
evaluate s erum concentration of M EDI8897 or palivizumab. The P K of M EDI8897 and
palivizumab will be mea s ured utilizing validated a ss ay s .
4.3.4 Ant i -drug  Ant i body  Eva l uat i on  and  Methods
Blood s ample s  will be collected to evaluate ADA re s pon s e s  to M EDI8897 and palivizumab in
serum ( s ee S ection 4.2.2 for collection time point s ). Evaluation will be performed u s ing
validated immunoa ss ay s . Tiered analy s e s  will be performed to include s creening,
confirmatory, and titer a ss ay comp o nent s , and the po s itive-negative cut point s  will be
statis tically determined from drug-naive validation s ample s . S ample s  will be utilized for
further characterization of the ADA re s pon s e, including ADA to the YTE domain on
MEDI8897 and the a ss e ss ment of neutralizing antibody to M EDI8897 or palivizumab.
4.3.5
4.3.5.1RSV-neutra li z i ng  Ant i body  and  RSV  Sero l ogy  Eva l uat i ons  and
Methods
RSV Ne u tralizi n g A n ti b o d y
Blood s ample s  will be collected to evaluate anti-R S V neutralizing antibody level s  in
serum ( s ee S ection 4.2.2 for collection time point s ). Analy s e s  will be performed
using an R S V neutralizing antibod y  a ss ay previou s ly de s cribed by S hambaugh et al
(Shambaugh et al, 2017 ).
[IP_ADDRESS] R S V S erology
Blood s ample s  will be collected to mea s ure R S V antigen- s pecific antibody level s  in s erum
(see S ection 4.2.2 for collection time point s ). Evaluation s  will be performed u s ing a validated
immunoa ss ay s imilar to the a ss ay de s cribed by M aifeld et al ( M aifeld et al, 2016 ).
4.3.6 Hea l thcare  Resource  Ut ili zat i on  and  Careg i ver  Burden
Information on HRU and caregiver burden will be collected for all event s  of medically
attended LRTI ( s ee Table 5 and Table 6 ). Thi s  will include admi ss ion to and duration of
hospi[INVESTIGATOR_330830] s ive care unit (IC U ) s tay, number of s ubject s  who require re s pi[INVESTIGATOR_330831] s upplemental oxygen use, duration of re s pi[INVESTIGATOR_696] s upport and s upplemental
oxygen u s e, number and type of outpatient vi s it s  (eg, ER, urgent care, outpatient clinic), and
the number of pre s cription and ove r -the-counter (OTC) medication s  and their duration of use.
Caregiver burden will be a ss e ss ed through, for example, caregiver mi ss ed work day s  and the
subject’ s  ab s ence from day care.
4.3.[ADDRESS_408916] i ons
Skin reaction a ss e ss ment will be done for any po s t-do s ing s kin or s kin-related reaction to
assis t in determination of the etiology of the reaction ( s ee Table 5 and Table 6 ). Information
CONFIDENTIAL AND PROPRIETARY 48 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
will be collected regardle ss  of event s everity, duration, time of on s et po s t do s ing, or
relation s hip to inve s tigational prod u ct. P arent s /legal repre s entative s  of s tudy s ubject s  will be
given a hyper s en s itivity card and in s tructed to call the s tudy s ite immediately for s ign s  of
hyper s en s itivity or allergic reaction. S ite s  mu s t notify M edImmune within [ADDRESS_408917] i mate  of  Vo l ume  of  B l ood  to  be  Co ll ected
Blood volume e s timate s  are provided by [INVESTIGATOR_44201] s it/ s tudy day for S ea s on 1 ( Table 9 ) and S ea s on 2
(Table 10 ).
Table 9 Vol u me of Bloo d  to b e Collecte d , S ea s o n  1
Visit / Study Day
Visit  1 / S c r ee n i ng or V i s it  2 / D a y 1
Visit  4 / D a y 31
Visit  8 / D a y 151
Visit  9 / D a y 361
TotalEstimat e d B l ood Vo l um e  (mL)
1.5 mL
1.5 mL
1.5 mL
1.5 mL
6.0 mL
Table 10 Vol u me of Bloo d  to b e Collecte d , S ea s o n  2
Visit / Study Day
Visit  12 / D a y 31
Visit  16 / D a y 151
Visit  17 / D a y 361
TotalEstimat e d B l ood Vo l um e  (mL)
 1.5 mL
 1.5 mL
1.5 mL
4.5 mL
4.4 Study  or  Study  Component  Suspension  or  Termination
MedImmune re s erve s  the right to temporarily s u s pend or permanently terminate thi s  s tudy o r
component of the s tudy at any time. The rea s on s  for temporarily s u s pending or permanently
terminating the s tudy may include but are not limited to the following:
1Death in any s ubject in which the cau s e of death i s  a ss e ss ed a s  related to inve s tigational
product (in thi s  ca s e the s tudy will be pau s ed for the s pon s or s afety review committee to
evaluate the event s )
2Anaphylactic reaction that i s  related to inve s tigational product ( s ee Appendix B for a
definition of anaphylaxi s ; in thi s  ca s e the s tudy will be pau s ed for the s pon s or s afety
review committee to evaluate the event s )
CONFIDENTIAL AND PROPRIETARY 49 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Table 11Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Iden tificatio n  o f  In ve s tigatio n al Pro du ct s
Inve st i gat i ona l  P r odu c t
Paliv iz um a bManufa c tu rer
Astra Z e n ecaConce nt r at i on and Fo r mu l at i on as Supp lie d
Supp lie d a s 50 mg (nom i n al ) p e r v ial  so l u ti on. Th e
soluti on c on tai ns 100 mg / mL p ali v iz um a b, 25 mM
Histi d i n e , 1.6 mM g l y ci n e , 12.5 mM c h l or i d e , pH 6.0.
The nom i n al  f ill  vo l um e  i s 0.5 mL.
HCl = hydro c h l or i d e;  w / v = w ei gh t/ vo l um e .
MEDI8897 and palivizumab will be s upplied to the s ite in open-labeled kit s . Each kit ha s  a
unique number printed on all label s  within the kit (ie, the outer carton label and the label o f
each vial ) .
[IP_ADDRESS] In ve s tigatio n al Pro du ct Insp ectio n
Each vial s elected for do s e admini s tration s hould be in s pected. Refer to Table [ADDRESS_408918] Complaint s ection
(Section 4 .5.1.4 ) for further in s truction s .
[IP_ADDRESS] Do s e Pre p aratio n  S te ps  a nd  Treatme n t A d mi n i s tratio n
The fir s t day of do s ing i s  con s idere d  Day 1.
Study drug ( M EDI8897, placebo, and palivizumab) will be s upplied by [CONTACT_330873]. Blinding will be performed at the s ite level to en s ure that
MEDI8897, placebo, and palivizumab are indi s tingui s hable in appearance and are not la b eled
to reveal treatment identity.
No incompatibilitie s  between M EDI8897 or palivizumab and polycarbonate or polypropylene
syringe s  have been ob s erved.
MEDI88 9 7 and palivizumab do not contain pre s ervative s  and any unu s ed portion mu s t be
discarded. Total in-u s e s torage time from needle puncture of the s tudy drug vial to
admini s t r ation s hould not exceed 4 hour s  at room temperature. If s torage time exceed s  these
limit s , a n ew vial s hould be u s ed.
CONFIDENTIAL AND PROPRIETARY 51 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
MED I 8897 gro up : S ea s o n  1 a nd  S ea s o n  2, i n cl ud i n g re p laceme n t d o s e( s ) after
card io p ulmo n ary b y p a ss
Subject s  will receive M EDI8897 for Do s e 1 and placebo for Do s e s  2 through 5:
1S ea s o n  1
(a) I nfant s  < 5 kg body weight at time of do s ing:
o Do s e 1: A do s e of 50 mg (ie, 0.5 mL) M EDI8897 will be obtained by
[CONTACT_330874] s  of 1 inve s tigational vial with an appropriately
sized s yringe, and admini s tered a s  one s ingle (ie, 0.5 mL) injection
o Do s e s  2 through 5: A corre s ponding volume (0.5 mL) of s aline will be obtained,
and admini s tered a s  one s ingle (ie, 0.5 mL) injection
(b) I nfant s  ≥ 5 kg body weight at time of do s ing :
o Do s e 1: A do s e of 100 mg (ie, 1.0 mL) M EDI8897 will be obtained by
[CONTACT_330874] s  of 2 inve s tigational vial s
o Do s e s  2 through 5: A corre s ponding volume (1.0 mL) of s aline will be
admini s tered
o To maintain the blind:
 If the weight i s  ≥ 5 kg to < 6.7 kg then the do s e s hould be admini s tered as
one s ingle (ie, 1.0 mL) injection
 If the weight i s  ≥ 6.7 kg, then the volume of M EDI8897 or s aline s hould be
divided equally int o  2 s yringe s
2S ea s o n  2
o D o s e 1: A do s e of 200 mg (ie, 2.0 mL) M EDI8897 will be obtained by [CONTACT_330875] s  of 4 inve s tigational vial s
o Do s e s  2 through 5: A corre s ponding volume (2.0 mL) of s aline will be admini s te r ed
o To maintain the blind:
 If the weight i s  < 13.4 kg, then the do s e s hould be admini s tered a s  two 1.0 mL
injection s  (ie, 1.0 mL per injection)
 If the weight i s  ≥ 13.4 kg, then the volume of M EDI8897 or s aline s hould be
divided equally into 3 sy ringe s
3Re p laceme n t d o s e( s ) after car d io pu lmo n ary b y p a ss
Seas o n  1
(a) Cardiopulmonary by[CONTACT_330843]  < 90 day s  po s t fir s t do s e of M EDI8897 (or mo s t recent
replacement do s e if previou s  cardiopulmonary by[CONTACT_330843] ) for infant s  < 5 kg:
o Replacement do s e: A do s e of 50 mg (ie, 0.5 mL) M EDI8897 will be obtained by
[CONTACT_330874] s  of 1 inve s tigational vial with an appropriately
sized s yringe, and admini s tered a s  one s ingle (ie, 0.5 mL) injection
CONFIDENTIAL AND PROPRIETARY 52 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
(b) Cardiopulmonary by[CONTACT_330843]  < 90 day s  po s t fir s t do s e of M EDI8897 (or mo s t recent
replacement do s e if previou s  cardiopulmonary by[CONTACT_330843] ) for infant s  ≥ 5 kg:
o Replacement do s e: A do s e of 100 mg (ie, 1.0 mL) M EDI8897 will be obtained
by [CONTACT_330874] s  of 2 inve s tigational vial s
o To maintain the blind:
 If the weight i s  ≥ 5 k g to < 6.7 kg then the do s e s hould be admini s tered as one
single (ie, 1.0 mL) injection
 If the weight i s  ≥ 6.7 kg, then the volume of M EDI8897 s hould be divided
equally into 2 s yringe s
(c) Cardiopulmonary by[CONTACT_330843]  ≥ 90 day s  po s t fir s t do s e (or mo s t recent replacement dose
if previou s  cardiopulmona r y by[CONTACT_330843] ) for all weight s :
o Replacement do s e: A do s e of 50 mg (ie, 0.5 mL) M EDI8897 will be obtained by
[CONTACT_330874] s  of 1 inve s tigational vial with an appropriately
sized s yringe, and admini s tered a s  one s ingle (ie, 0.5 mL) injection
Seaso n  2
(a) Cardiopulmonary by[CONTACT_330843]  < 90 day s  po s t fir s t do s e:
o Replacement do s e: A do s e of 200 mg (ie, 2.0 mL) M EDI8897 will be obtained
by [CONTACT_330874] s  of 4 inve s tigational vial s
o To maintain the blind:
 If the weight i s  < 13.4 kg, then the do s e s hould be admini s tered a s  two 1 . 0 mL
injection s  (ie, 1.0 mL per injection)
 If the weight i s  ≥ 13.4 kg, then the volume of M EDI8897 s hould be divided
equally into 3 s yringe s
(b) Cardiopulmonary by[CONTACT_330843]  ≥ 90 day s  po s t fir s t do s e (or mo s t recent replacement dose
if previou s  cardiopulmona r y by[CONTACT_330843] ):
o Replacement do s e: A do s e of 100 mg (ie, 1.0 mL) M EDI8897 will be obtained
by [CONTACT_330876] e n tire content s  of 2 inve s tigational vial s
o To maintain the blind:
 If the weight i s  ≥ 5 kg to < 6.7 kg then the do s e s hould be admini s tered as one
single (ie, 1.0 mL) injection
 If the weight i s  ≥ 6.7 kg, then the volume of M EDI8897 s hould be divided
equally into 2 s yringe s
4S witch the needle prior to admini s tration
5 M EDI8897 or placebo ( s aline) s hould be admini s tered in the anterolateral a s pect of the
thigh according to s tandard practice procedure s  for I M  injection s . The injection s hould be
given u s ing s tandard a s eptic technique. When po ss ible, injection s ite s  for s ub s equent
injection s  s hould u s e alternating s ite s  (eg, right then left thigh). The maximum volume to
be admini s tered with each injection i s  1.0 mL
6M EDI8897 or placebo ( s aline) s hould be admini s tered u s ing the appropriate s ize needle
ranging from 22 to 25 gauge and 5/[ADDRESS_408919]
CONFIDENTIAL AND PROPRIETARY 53 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Paliviz um a b  gro up : S ea s o n  1 a nd  S ea s o n  2, i n cl ud i n g re p laceme n t d o s e( s ) after
card io p ulmo n ary b y p a ss
1 A do s e of 15 mg/kg palivizumab will be obtained by [CONTACT_330877] s t 0.01 mL a s  de s cribed below:
The do s e of palivizumab will be calculated ba s ed on the s ubject’ s  weight (to the nearest
0.01 kg) u s ing the following formula:
Dose (mL) = [ s ubject weight (kg) × do s e level (15 mg/kg)] ÷
palivizumab concentration (100 mg/mL)
The corre s ponding volume of palivizumab s hould be rounded to the neare s t 0.01 mL.
Example s :
A patient who weigh s  4.90 kg at the time of injection r eceive s  0.74 m L  of s tudy d rug
(4.90 kg x 15 mg/kg) ÷ 100 mg/m L  = 0.735 m L  ( r ounded to 0.74 m L )
A patient who weigh s  3.70 kg at the time of injection r eceive s  0.56 m L  of s tudy d rug
(3.70 kg x 15 mg/kg) ÷ 100 mg/m L  = 0.555 m L  ( r ounded to 0.56 m L )
2S witch the needle prior to admini s tration
3P alivizumab s hould be administered in the anterolateral a s pect of the thigh according to
stand ard practice procedure s  f o r I M  injection s . The injection s hould be given u s ing
standard a s eptic technique. When po ss ible, injection s ite s  for s ub s equent injection s
should u s e alternating s ite s  (eg, right then left thigh). The maximum volume to be
admini s tered with each injection i s  1 mL
4P ali v izumab s hould be administered u s ing the appropriate s ize needle ranging from 22 to
25 gauge and 5/[ADDRESS_408920]
[IP_ADDRESS] Mo n itori n g of Do s e A d mi n i s tratio n
Subject s  will be monitored before and after inve s tigational product admini s tration through
assess ment of vital s ign s  (temperature, blood pre ss ure, heart rate, and re s pi[INVESTIGATOR_697]). All
vital s ign s  s hould be obtained within 60 minute s  prior to do s ing, and at 30 minute s
(± 5 minute s ) and 60 minute s  (± 5 minute s ) po s t do s e.
As with any biologic product, allergic reaction s  to do s e admini s tration are po ss ible. There f o r e,
appropriate drug s  and medical equipment to treat acute anaphylactic reaction s  mu s t be
immediately available, and s tudy per s onnel mu s t be trained to recognize and treat
anaphylaxi s .
CONFIDENTIAL AND PROPRIETARY 54 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
[IP_ADDRESS] Re p orti n g Pro du ct Com p lai n t s
Any defect s  with the inve s tigational product mu s t be reported immediately to the M edImmune
Product Complaint Department by [CONTACT_941] s ite with further notification to the s ite monitor. All
defect s  w ill be communicated to M edImmune and inve s tigated further with the P roduct
Complaint Department. During the inve s tigation of the product complaint, all inve s tigati o nal
product mu s t be s tored at labeled condition s  unle ss  otherwi s e in s tructed.
MedImmune contact [CONTACT_3031] f o r reporting product complaint s :
Email:
Phone:
Mail: M edImmune
Attn: P roduct Complaint Department
Gaither s bur g , M D U S A [ADDRESS_408921] will be prepared in accordance with Good
Manufacturing P ractice and local regulatory guideline s . Label text will be tran s lated into local
language s , a s  required.
4.5.4 Storage
Store M EDI8897 and palivizumab at 2°C to 8°C. P lacebo ( s aline) s hould be s tored accor d ing
to the manufacturer in s truction s .
4.5.[ADDRESS_408922] i s  admini s tered by s tudy s ite per s onnel, who will monitor compliance.
4.5.6 Accountab ili ty
The investigator ’ s  or s ite’ s  de s ignated inve s tigational product manager i s  required to maintain
accurate inve s tigational product accountability record s . Upon completion of the s tudy, copi[INVESTIGATOR_330832] s tigational product accountability record s  will be returned to M edImmune. All unused
MEDI8897 and palivizumab will be returned to a M edImmune-authorized depot or di s posed
of upon authorization by M edImm u ne.
CONFIDENTIAL AND PROPRIETARY 55 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
4.[ADDRESS_408923] s  in the preterm and CLD/CHD cohort s  will be randomized u s ing a
2:1 ratio to either the M EDI8897 group or palivizumab group. Within each cohort, the
randomization will be s tratified by [CONTACT_330852] s phere (northern, s outhern) and s ubject age at the time
of Sea s on 1 randomization ( ≤ 3 mo n th s , > 3 to ≤ 6 month s , > 6 month s ).
In Sea s o n  2, s ubject s  in the CLD/C H D cohort only will be randomized. S ubject s  who we r e
randomized to the M EDI8897 group in S ea s on [ADDRESS_408924] s  who were randomized to the CLD/CHD group in S ea s on 1 will be re-randomized
using a 1:[ADDRESS_408925] u g ( M EDI8897, placebo, o r  palivizumab) mu s t be admini s tered the s ame day the
study drug i s  a ss igned. If there i s  a delay in the admini s tration of s tudy drug s uch that it will
not be admini s tered within the s pecified timeframe, the unblinded inve s tigational product
monitor mu s t be notified immediately.
4.6.[ADDRESS_408926]/legal
repre s entative nor the inve s tigator o r any of the s ite s taff who are involved in the treatment o r
clinical evaluation of the s ubject s  will be aware of the treatment received (ICH E9). In the
event that treatment allocation for a s ubject become s  known to the inve s tigator or other
blinded s tudy s taff involved in the management of s tudy s ubject s , the s pon s or mu s t be noti f ied
immediately . If the treatment allocation for a s ubject need s  to be known to treat an individual
subject for an AE, the inve s tigator mu s t notify the s pon s or immediately . The s ite will maintain
a written plan detailing which s taff member s  are blinded/unblinded and the proce ss  of
inves tigational product admini s tration u s ed to maintain the blind.
4.6.[ADDRESS_408927]’s
inves tigational product allocation. In s truction s  for unblinding an individual s ubject’ s  s tudy
drug allocation are contained in the IWR S  manual. In general, unblinding s hould only occu r  i f
CONFIDENTIAL AND PROPRIETARY 56 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
management of the medical emergency would be different ba s ed on the s ubject having
received s tudy drug. In the majorit y  of ca s e s , the management of a medical emergency w ould
be the s ame whether or not s tudy drug wa s  received by [CONTACT_941] s ubject. If thi s  wa s  the ca s e, the
study drug allocation s hould not be unblinded. In the event there i s  unblinding, the
inves tigator s hould promptly document and explain to M edImmune the rea s on for any
premature unblinding.
MedImmune retain s  the right to unblind the treatment allocation for S AE s  that are unexpected
and are sus pected to be cau s ally related to a s tudy drug and that potentially require expe d ited
reporting to regulatory authoritie s .
If a s ubject’ s  s tudy drug allocation i s  unblinded to the blinded s taff or blinded
MedImmune/contract re s earch organization s tudy team, the s ubject s hould be di s continued
from s tudy drug.
4.7 Restrictions  During  the  Study  and  Concomitant  Treatment(s)
The investigator mu s t be informed a s  s oon a s  po ss ible about any medication taken from the
time of s creening until the final s tudy vi s it. Any concomitant medication( s ), including he r bal
preparation s , taken during the s tud y  will be recorded in the electronic ca s e report form
(eCR F ).
4.7.[ADDRESS_408928] s , and treatment with antibi o tic s , anti-emetic s , anti-diarrheal s , and analge s ic s , an d
other care a s  deemed appropriate, and in accordance with their in s titutional guideline s .
4.7.2 Proh i b i ted  Concom i tant  Med i cat i ons
Use of concomitant medication s  including over-the-counter medication s  (except for routine
vitamin s  and iron), herbal s upplement s , etc from Day [ADDRESS_408929]’ s  legal repre s entative mu s t be in s tructed not to admini s ter any
medicati o n s , including over-the-counter product s , without fir s t con s ulting with the
inves tigator.
4.[ADDRESS_408930] s  in each category. Continuou s  variable s  will be
CONFIDENTIAL AND PROPRIETARY 57 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
summarized by [INVESTIGATOR_5328] s criptive s tati s tics. Additional detail s  of s tati s tical analy s e s  will be
described in the s tati s tical analy s i s  plan.
The Intent-to-treat (ITT) P opulation i s  defined a s  all randomized s ubject s , analyzed acco r ding
to randomized treatment a ss ignment. All efficacy analy s e s  will be performed on the ITT
Population.
The A s -treated P opulation (AT P ) i s  defined a s  all s ubject s  who receive any inve s tigational
product, analyzed according to treatment received. All analy s e s , with the exception of
efficacy, will be performed on the AT P  unle ss  otherwi s e s pecified.
A prima r y analy s i s , S ea s on [ADDRESS_408931] completed follow-up
through the fir s t 5-month R S V s ea s on (ie, S ea s on 1 Day 151 vi s it) and include all available
Season 1 s afety, efficacy, P K, and ADA data at the time of the data cutoff. S ea s on 2 anal y sis
will be conducted after all the CLD/CHD s ubject s  have completed follow-up through the
second 5-month R S V s ea s on (ie, S ea s on 2 Day 151 vi s it) and include all available S ea s on [ADDRESS_408932] completed the la s t vi s it of the s tudy and
include all data collected in the s tudy.
At the time of the primary analy s i s , the S ea s on 1 data will be unblinded to the
Spon s or/de s ignated clinical re s earc h  organization a ss ociated with the analy s i s , write-up, and
regulato r y s ubmi ss ion.
To en s ure the blinding of S ea s on 2 treatment a ss ignment for CLD/CHD s ubject s  who we r e
randomized to the palivizumab arm in S ea s on 1, any data with potential unblinding ri s k w ill
be split by S ea s on [ADDRESS_408933] s  and/or day-to-day interaction s  with the s ite, will remain
blinded until the end of the s tudy to en s ure the trial integrity i s  maintained. F urther details will
be specified in the unblinding plan p rior to databa s e lock for the primary analy s i s .
4.8.[ADDRESS_408934] s  expo s ed to M EDI8897 in S ea s on 1 will provide a
95% probability of ob s erving at lea s t one AE if the true event rate i s  0.5%; if no AE s  are
observed, thi s  s tudy provide s  95% confidence that the true event rate i s  < 0.5%. The s ample
size i s  fo r  s afety con s ideration.
CONFIDENTIAL AND PROPRIETARY 58 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
With re s pect to efficacy, approximately [ADDRESS_408935] s  w ill be expo s ed to palivizumab in S ea s on 1 to ob s erve numerically s imilar efficacy
for both mAb s . Becau s e of the reduced incidence of R S V di s ea s e in thi s  population follo w ing
the introduction of palivizumab, a su periority or non-inferiority de s ign i s  not practical. A  valid
non-inferiority margin cannot be e s tabli s hed due to the lack of hi s torical efficacy data for the
medically attended R S V LRTI endpoint for palivizumab. Therefore, there i s  no hypothe s is
testing for efficacy. U s ing an a ss umption of a 6% R S V LRTI rate in palivizumab recipi[INVESTIGATOR_840],
approximately 18 event s  will be ob s erved in that group. The 6% R S V LRTI rate (1.9% R S V
hospi[INVESTIGATOR_059] s  and 3.9% outpatie n t R S V illne ss ) wa s  ba s ed on a prior s tudy in preterm
infant s  w ith and without CLD who received palivizumab ( Carbonell-E s trany et al, 2010 ).
Assuming a 6% rate of R S V LRTI in M EDI8897 recipi[INVESTIGATOR_841] s , [ADDRESS_408936] s  in
Season 1 will provide approximately 36 event s  in that group. However, becau s e of the la r gely
reduced R S V circulation due to COVID-19 pandemic-related mea s ure s , the ob s erved event
rates  could be much lower. Only s ummarie s  will be provided for efficacy unle ss  s pecified
otherwi s e.
4.8.3
4.8.3.1Safety
Analy s i s  of A d ver s e E v e n t s
AEs will be graded according to the current ver s ion of the NCI CTCAE where applicable f o r
pediatric a ss e ss ment s . AE s  will be coded by [CONTACT_941] M edical Dictionary for Regulatory Activities
and the type, incidence, s everity, a n d relation s hip to s tudy drug will be s ummarized by
[CONTACT_1570]. Other s afety a ss e s sment s  will include the occurrence of AE S I s  defined as
AEs of h y per s en s itivity to s tudy drug (including anaphylaxi s ), thrombocytopenia, and
immune complex di s ea s e (eg, va s culiti s , endocarditi s , neuriti s , glomerulonephriti s ) follo w ing
study drug admini s tration, and the occurrence of NOCD s  following s tudy drug admini s tration.
Safety of M EDI8897 will be s ummarized by [CONTACT_330878] s ed on the AT P . The s afety
summary will be provided for each s ea s on, a s  well a s  for the 2 con s ecutive R S V s ea s on s
(ie, S ea s on 1 and S ea s on 2). F or the S ea s on [ADDRESS_408937] s  from the preterm cohort and CLD/CHD cohort, pre s ented by [CONTACT_330879] s on 1; for the S ea s on [ADDRESS_408938] s  from the CLD/CHD cohort, pre s ented by [CONTACT_330880] 2 s ea s on s .
4.8.4 Eff i cacy
The primary efficacy endpoint i s  the incidence of medically attended R S V LRTI (inpatient
and outpatient) through 150 day s  po s t Do s e 1 (ie, during a typi[INVESTIGATOR_2855] 5-month R S V s ea s on) in
Season 1. The determination of the primary efficacy endpoint will be ba s ed on R S V te s t
result s  (performed centrally u s ing real-time RT- P CR; s ee S ection [IP_ADDRESS] ) and objective
protocol-defined LRTI criteria ( s ee Table 7 and Table 8 ), and will be s ummarized by S eason 1
CONFIDENTIAL AND PROPRIETARY 59 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
treatment group for all [ADDRESS_408939] s . The 95% CI of the percentage of s ubject s  meeting the
primary efficacy endpoint will be p r e s ented by [CONTACT_1570]. F or s ubject s  with multiple
medically attended R S V LRTI eve n t s , only the fir s t occurrence will be u s ed in the primary
efficacy s ummary.
In additi o n, the s ummary of incide n ce of R S V LRTI through [ADDRESS_408940] s  in the CLD/CHD cohort ba s ed on the treatment
assignment s  through S ea s on 1 and Sea s on 2: ie, (a) 50 mg M EDI8897 for infant s  with body
weight < 5 kg and 100 mg M EDI8897 for infant s  with body weight ≥ 5 kg ( S ea s on 1)/200 mg
MEDI8897 ( S ea s on 2), (b) palivizumab ( S ea s on 1)/200 mg M EDI8897 ( S ea s on 2), and
(c) palivizumab ( S ea s on 1)/palivizumab ( S ea s on 2).
The inci d ence of R S V ho s pi[INVESTIGATOR_151400] 150 day s  after do s ing (ie, during the 5-mo n th
RSV s ea s on) will be s ummarized by [CONTACT_1570] u s ing a s imilar s trategy a s  de s cribe d
above for R S V LRTI.
Additional analy s e s  will include s ummarizing R S V-po s itive LRTI endpoint s  u s ing re s ult s
from either the central laboratory or local laboratory.
All efficacy s ummarie s  will be ba s ed on the ITT P opulation.
4.8.5
4.8.5.1Anal ys i s  of  Pharmacok i net i cs  and  Ant i -drug  Ant i body
Pharmaco k i n etic A n aly s i s
Individual M EDI8897 and palivizumab s erum concentration data will be tabulated by
[CONTACT_330881] s criptive s tati s tic s . P K parameter s , eg, maximum ob s erved
concentration (C max ), AUC, apparent clearance, and t 1 / 2  will be e s timated u s ing
non-compartmental analy s i s , if data permit.
[IP_ADDRESS] A n ti- d r u g A n ti b o d y A n aly s i s
The incidence of ADA to M EDI8897 and to palivizumab will be a ss e ss ed and s ummarized by
[CONTACT_330882] s ubject s  w ho are ADA po s itive by [CONTACT_1570]. The impact o f
ADA on P K, and a ss ociation with TEAE s  and TE S AE s , will be a ss e ss ed.
4.8.[ADDRESS_408941] oratory  Ana l yses
RSV Ne u tralizi n g A n ti b o d y
Individual M EDI8897 and palivizumab s erum anti-R S V neutralizing antibody level s  will be
tabulated by [CONTACT_330883] w ith de s criptive s tati s tic s . Anti-R S V neutralizing antibody
level s  in s erum will be s ummarized by [CONTACT_330884]-fold ri s e and
corre s ponding 95% CI for each treatment group at each vi s it. Anti-R S V neutralizing antibody
level t 1 / 2  will be e s timated u s ing non-compartmental analy s i s , if data permit.
CONFIDENTIAL AND PROPRIETARY 60 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
[IP_ADDRESS] R S V S erology
Analy s i s  of anti-R S V antigen s  antibody level s  in s erum in M EDI8897 and palivizumab
recipi[INVESTIGATOR_95074] s ummarized by [CONTACT_330884]-fold ri s e and
corre s ponding 95% CI for each treatment group at each vi s it. S erore s pon s e s  in M EDI88 9 7
and palivizumab recipi[INVESTIGATOR_841] s  will be determined by [CONTACT_330885]-ri s e in antibodie s  t o  Ga,
Gb, and N antigen s .
[IP_ADDRESS] Healt h care Re s o u rce U tilizatio n  a nd  Caregiver B u r d e n
The mag n itude of HRU (eg, number of admi ss ion s  to ho s pi[INVESTIGATOR_307] s  and ICU s  and duration of stay;
number of s ubject s  who require re s pi[INVESTIGATOR_696] s upport and s upplemental oxygen and the duration
of us e; number and type s  of outpatient vi s it s , eg, ER, urgent care, outpatient clinic; and
number o f pre s cription and OTC medication s  and duration of u s e) will be s ummarized o v e r all
by [CONTACT_28459] s ubject s  with at lea s t one medically attended LRTI (protocol
defined) cau s ed by [CONTACT_937]- P CR-confirmed R S V.
Caregiver burden (eg, caregiver mis s ed work day s , s ubject ab s ence from day care) for s ubjects
with medically attended LRTI (protocol defined) cau s ed by [CONTACT_937]- P CR-confirmed R S V will be
summarized by [CONTACT_1570].
The HR U  and caregiver burden s ummarie s  will be performed on the ITT P opulation.
[IP_ADDRESS] R S V Re s i s ta n ce Mo n i t ori n g
RSV ge n otypic analy s i s  will report the s equence change s  in the mature F  protein from all
RSV po s itive i s olate s  compared to contemporary R S V A and R S V B reference s train s .
Susceptibility of novel R S V variant s  to M EDI8897 and palivizumab will be te s ted and
compared to control viru s e s .
[IP_ADDRESS] R S V LRT I  Occ u rri n g From Day 152 to Day 361
The incidence of medically attended R S V LRTI (inpatient and outpatient) from Day 152 to
Day 361 for S ea s on 1 and S ea s on 2 will be ba s ed on R S V te s t re s ult s  (performed centrally via
RT-P CR )  and objective clinical LRTI criteria and will be s ummarized by [CONTACT_1570].
4.8.[ADDRESS_408942] a
CONFIDENTIAL AND PROPRIETARY 61 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
causal relation s hip with thi s  treatment. An AE can therefore be any unfavorable and
unintended s ign (eg, an abnormal laboratory finding), s ymptom (eg, nau s ea, che s t pain), o r
disea s e temporally a ss ociated with the u s e of a medicinal product, whether or not con s ide r ed
related to the medicinal product.
The term AE i s  u s ed to include bot h  s eriou s  and non- s eriou s  AE s  and can include a
deterioration of a pre-exi s ting medical occurrence. An AE may occur at any time even if no
study treatment ha s  been admini s te r ed.
Elective treatment or s urgery or preplanned treatment or s urgery (that wa s  s cheduled prio r  to
the subject being enrolled into the s tudy) for a documented pre-exi s ting condition that did not
wors en from ba s eline i s  not con s idered an AE ( s eriou s  or non s eriou s ). An untoward medical
event occurring during the pre s cheduled elective procedure or routinely s cheduled treatment
should be recorded a s  an AE or S AE.
5.2 Definition  of  Serious  Adverse  Events
An S AE i s  any AE that:
Re s ult s  in death
I s  immediately life-threatening
Require s  inpatient ho s pi[INVESTIGATOR_330833] s ting ho s pi[INVESTIGATOR_059]
Re s ult s  in per s i s tent or s ignificant di s ability/incapacity
I s  a congenital anomaly/birth defect in off s pring of the s ubject
I s  an important medical event that may jeopardize the s ubject or may require medical
intervention to prevent one of the outcome s  li s ted above
Medical o r s cientific judgment s hould be exerci s ed in deciding whether expedited reporting is
appropriate in thi s  s ituation. Exam p le s  of medically important event s  are inten s ive treatment
in an ER or at home for allergic broncho s pa s m, blood dy s cra s ia s , or convul s ion s  that do not
result in ho s pi[INVESTIGATOR_059] s .
5.[ADDRESS_408943].
CONFIDENTIAL AND PROPRIETARY 62 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
5.3.1 Hypersens i t i v i ty,  Inc l ud i ng  Anaphy l ax i s
Admini s tration of polyclonal immunoglobulin preparation s  and mAb s  ha s  been a ss ociated
with immediate (type I) hyper s en s itivity (including anaphylaxi s ) that occur s  during or afte r
dosing. An immediate hyper s en s itivity reaction i s  defined a s  an acute on s et of an illne ss  w ith
involvement of the s kin, muco s al ti ss ue, or both during admini s tration of inve s tigational
product (but doe s  not meet the definition of anaphylaxi s ). Anaphylaxi s  i s  a rare event, u s ually
occurrin g  after s ub s equent expo s ure to antigen, and it i s  mo s t commonly accompanied by
[CONTACT_86525] s y s temic s kin and or muco s al reaction s . It i s  potentially a fatal, s y s temic allergic
reaction that i s  di s tinct from s imple allergic reaction s  (eg, ra s h, pruritu s ) becau s e of the
simultaneou s  involvement of s everal organ s y s tem s  ( S amp s on et al, 2006 ). A full definition o f
anaphylaxi s  i s  provided in Appendix B . S ee S ection 5.5 for recording AE s .
5.3.2 Immune  Comp l ex  D i sease
Immune complex di s ea s e can mani f e s t in the form of a number of condition s  s uch a s
vasculitis, endocarditi s , neuriti s , gl o merulonephriti s , s erum s ickne ss , and arthralgia s .
Drug-induced immune complex (type III) hyper s en s itivity reaction s  can occur when ho s t
immune s y s tem generate s  antibodie s  to drug re s ulting in s oluble circulating antigen-anti b ody
complexe s  formation and their dep os ition in blood ve ss el s . S ub s equently thi s  initiate s  ti s sue
damaging inflammatory reaction s  mediated by [CONTACT_316779]/or leukocyte s  and ma s t cells.
The pathology and clinical manife s tation s  are dependent on the ti ss ue s /organ s  involved, with
vascular, s kin and renal ti ss ue s  being common s ite s  of injury. Common example s  of immune
complex hyper s en s itivity reaction s  are s erum s ickne ss  ( s y s temic) and Arthu s  reaction s  (local ) .
The clinical manife s tation s  of s erum s ickne ss  include s kin ra s h, fever, malai s e, and
polyarthralgia s  or polyarthriti s . S ymptom s  typi[INVESTIGATOR_316725] 1 to 2 week s  after fir s t exposu r e
to antigen and u s ually re s olve in s everal week s  after withdrawal of the cau s ative agent. Se r um
sickne ss  n eed s  to be differentiated f rom other ‘ s erum- s ickne ss -like’ reaction s  that have a
similar clinical pre s entation (eg, viral infection s , anti- s eizure drug s ), but are believed to have
different pathogenic mechani s m s . Both s erum s ickne ss  and s erum s ickne ss -like reaction s  have
been reported with mAb s  (eg, rituximab, infliximab). Clinical pre s entation and time to onset
should be taken into account for the diagno s i s  and differentiation of the s e reaction s . Diagnosis
of the s e su s pected reaction s  i s  be s t confirmed via biop s y of the affected ti ss ue s . S ee
Section 5.5 for recording AE s .
5.3.3 Thrombocytopen i a
Thrombocytopenia i s  a di s order in w hich there i s  an abnormally low platelet count; a normal
platelet count range s  from 150,000 to 450,000 platelet s  per μL. The 3 major cau s e s  of low
platelet count s  include: (1) in s ufficient platelet s ynthe s i s  in the bone marrow; (2) increa s ed
breakdo w n of platelet s  in the blood s tream; and (3) increa s ed breakdown of platelet s  in the
spleen or liver. General s ymptom s  of thrombocytopenia include bleeding in the mouth a n d
gums , brui s ing, no s ebleed s , and petechiae (pi[INVESTIGATOR_330834] s pot s /ra s h). S evere bleeding i s  the
CONFIDENTIAL AND PROPRIETARY 63 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
major complication, which may occur in the brain or ga s trointe s tinal tract. Drug-induced
thrombocytopenia i s  a rever s ible form of thrombocytopenia that s hould be s u s pected in a
subject w ho pre s ent s  with new on s et thrombocytopenia or recurrent epi s ode s  of acute
thrombocytopenia, without an obviou s  alternative etiology. It i s  commonly induced by d r ug
depende n t antibodie s  that cau s e platelet de s truction or clearance by [CONTACT_330886] (drug-induced immune thrombocytopenia), and le ss  commonly by [CONTACT_9934]-induced bone
marrow suppre ss ion or autoimmune thrombocytopenia that i s  initiated by [CONTACT_330887] s ure to the
offending drug but per s i s t s  in it s  ab s ence. The initial approach to the s ubject with s u s pected
drug-ind u ced thrombocytopenia involve s  confirming thrombocytopenia, e s tabli s hing a
temporal relation s hip to a drug, and eliminating other cau s e s  of thrombocytopenia. The
diagno s i s  i s  made clinically by [CONTACT_330888] s olution of thrombocytopenia afte r
discontinuation of the s u s pected drug (typi[INVESTIGATOR_16195] 1 week). M o s t s ubject s  with
drug-induced thrombocytopenia require no s pecific treatment, a s  their platelet count s  will
recover promptly following withdrawal of the cau s ative agent. S ee S ection 5.[ADDRESS_408944] and i s  a ss e ss ed by [CONTACT_132366] s tigator a s
medicall y  s ignificant. Example s  of NOCD s  include, but are not limited to diabete s ,
autoimmune di s ea s e (eg, lupu s , rheumatoid arthriti s ), and neurological di s ea s e (eg, epi[INVESTIGATOR_002] ) .
Event s  t h at would not be con s idered a s  NOCD s  are mild eczema, diagno s i s  of a congenital
anomaly pre s ent at s tudy entry, or acute illne ss  (eg, upper re s pi[INVESTIGATOR_4416], otiti s  media,
bronchiti s ). S ee S ection 5.[ADDRESS_408945], po ss ible etiologies,
and whether the event meet s  criteria of an S AE and therefore require s  immediate notification
to M edImmune ( s ee S ection 5.6). S ee S ection 5.2 for the definition of S AE s  and Appendix A
for guideline s  for a ss e ss ment of s everity and relation s hip.
If an AE evolve s  into a condition that meet s  the regulatory definition of “ s eriou s ,” it will be
reported on the S AE Report F orm.
5.5.[ADDRESS_408946] i on  of  Adverse  Events
AEs and S AE s  will be recorded from the time of s ignature of informed con s ent through t h e
follow-up period (Day 361).
CONFIDENTIAL AND PROPRIETARY 64 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
All AE S I s  and NOCD s  will be rec o rded from the time of do s ing with s tudy drug through the
follow-up period (Day 361).
5.5.[ADDRESS_408947]’ s  la s t vi s it in the s tudy are followed up by [CONTACT_330889] a s  long a s  medically indicated, but without further recording in the eCR F .
MedImmune retain s  the right to reque s t additional information for any s ubject with ongoing
AE(s )/ S AE( s ) at the end of the s tudy, if judged nece ss ary.
5.5.[ADDRESS_408948]-mo r tem (autop s y) may be helpful in the a ss e ss ment of the cau s e of death, and if
performed a copy of the po s t-mortem re s ult s  s hould be forwarded to M edImmune
repre s entative( s ) within the u s ual timeframe s  (refer to S ection 5.6 for additional information ) .
5.5.4 Adverse  Events  Based  on  S i gns  and  Symptoms
All AE s  spontaneou s ly reported by [CONTACT_330890] s pon s e to the open
question from the s tudy s ite s taff: ‘Ha s  the child had any health p r oblem s  s ince the p r evious
visit?’, or revealed by [CONTACT_330891] s ervation w ill be collected and recorded in the eCR F . When
collecting AE s , the recording of diagno s e s  i s  preferred (when po ss ible) to recording a li s t o f
signs  an d  s ymptom s . However, if a diagno s i s  i s  known and there are other s ign s  or s ymptoms
that are not generally part of the diagno s i s , the diagno s i s  and each s ign or s ymptom will b e
recorded s eparately.
5.5.5 Adverse  Events  Based  on  Exam i nat i on  and  Tests
An abnormal laboratory finding that require s  medical intervention by [CONTACT_132366] s tigator, or a
finding j u dged by [CONTACT_132366] s tigator a s  medically s ignificant s hould be reported a s  an AE. I f
clinical s equelae are a ss ociated with a laboratory abnormality, the diagno s i s  or medical
condition s hould be reported (eg, renal failure, hematuria) not the laboratory abnormality ( eg,
elevated creatinine, urine red blood cell increa s ed)
If deterioration in a laboratory value/vital s ign i s  a ss ociated with clinical s ign s  and s ymptoms,
the s ign or s ymptom will be reported a s  an AE and the a ss ociated laboratory re s ult/vital sign
will be con s idered a s  additional information. Wherever po ss ible the reporting inve s tigato r
uses the clinical, rather than the lab o ratory term (eg, anemia ver s u s  low hemoglobin value ) . I n
the ab s ence of clinical s ign s  or s ymptom s , clinically relevant deterioration s  in non-mandated
parameter s  s hould be reported a s  AE( s ).
Any new or aggravated clinically relevant abnormal medical finding at a phy s ical examination
as compared with the ba s eline a ss e ss ment will be reported a s  an AE.
CONFIDENTIAL AND PROPRIETARY 65 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
5.[ADDRESS_408949], or to the s tudy procedure( s) . All S AE s  will be recorded in the eCR F .
If any S AE occur s  in the cour s e of the s tudy, then inve s tigator s  or other s ite per s onnel must
inform the appropriate s pon s or repre s entative( s ) within 1 day, ie, immediately but n o later
than  24 h o u r s  after becoming awa r e of the event.
The de s ignated s tudy repre s entative work s  with the inve s tigator to en s ure that all the
necess ary information i s  provided to the s pon s or’ s  patient s afety data entry s ite within
1 calendar day of initial receipt for f atal and life-threatening event s  and within 5 calenda r  days
of initial receipt for all other S AE s .
For fatal or life-threatening AE s  w h ere important or relevant information i s  mi ss ing, active
follow-u p  i s  undertaken immediately. Inve s tigator s  or other s ite per s onnel inform s pon sor
repre s entative s  of any follow-up in f ormation on a previou s ly reported S AE within 1 calenda r
day, ie, immediately but n o later tha n  24 h o u r s  after becoming aware of the event.
Once the inve s tigator s  or other s ite per s onnel indicate an AE i s  s eriou s  in the electronic data
capture (EDC) s y s tem, an automated email alert i s  s ent to inform the de s ignated s pon s or
repre s entative( s ).
If the EDC s y s tem i s  not available, then the inve s tigator or other s tudy s ite per s onnel repo r ts
an SAE to the appropriate s pon s or r epre s entative by [CONTACT_756]. The s pon s or repre s entative
will advi s e the inve s tigator/ s tudy s ite per s onnel how to proceed.
5.[ADDRESS_408950] in exce ss  o f
that s pecified in the IB, unle ss  otherwi s e s pecified in thi s  protocol.
An overdo s e with a ss ociated AE s  i s  recorded a s  the AE diagno s i s / s ymptom s  on the
relev ant AE module s  in the eCR F  and on the Overdo s e eCR F  module.
 An overdo s e without a ss ociate d  s ymptom s  i s  only reported on the Overdo s e eCR F
modu le.
If an ove r do s e on a M edImmune in v e s tigational product occur s  during the cour s e of the study,
then the inve s tigator or other s ite per s onnel s hould inform appropriate s pon s or repre s entatives
immediately, but n o later t h a n  24 ho u r s  after becoming aware of the event.
CONFIDENTIAL AND PROPRIETARY 66 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
The de s ignated s pon s or repre s entative work s  with the inve s tigator to en s ure that all relevant
information i s  provided to the s ponsor’ s  P atient S afety data entry s ite.
For overdo s e s  a ss ociated with an S AE, the s tandard reporting timeline s  apply; s ee S ectio n  5.6.
For othe r  overdo s e s  (ie, tho s e not a ss ociated with an AE or S AE), reporting mu s t occur w ithin
[ADDRESS_408951].
Medication error include s  s ituation s  where an error:
Occurred
Wa s  identified and intercepted before the s ubject received the drug
Did n ot occur, but circum s tance s  were recognized that could have led to an error
Examples of event s  to be reported in clinical s tudie s  a s  medication error s :
Di sp en s ing error, eg, medicati o n prepared incorrectly, even if it wa s  not actually given to
the subject
Drug not admini s tered a s  indicated, eg, wrong route or wrong s ite of admini s tration
Dru g  not s tored a s  in s tructed, eg, kept at room temperature when it s hould be in the
refrigerator
Wrong s ubject received the medication (excluding IWR S  error s )
Wrong drug admini s tered to s ubject (excluding IWR S  error s )
Example s  of event s  that d o n ot  require reporting a s  medication error s  in clinical s tudie s :
Erro rs  related to or re s ulting from IWR S  - including tho s e which lead to one of the above
listed event s  that would other w i s e have been a medication error
Accidental overdo s e (will be captured a s  an overdo s e)
Medication error s  are not regarded a s  AE s  but AE s  may occur a s  a con s equence of the
medicati o n error.
CONFIDENTIAL AND PROPRIETARY 67 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
If a medication error occur s  in the cour s e of the s tudy, then the inve s tigator or other s ite
personnel inform s  the appropriate MedImmune repre s entative s  within 1 day, ie, immediately
but n o later t h a n  24 h o u r s  of whe n  he or s he become s  aware of it.
The de s ignated M edImmune repre s entative work s  with the inve s tigator to en s ure that all
relevant information i s  completed w ithin 1 or 5 calendar day s  if there i s  an S AE a ss ociated
with the medication error ( s ee S ection 5.6) and within [ADDRESS_408952]
Hyper s e ns itivity, In clu d i n g A n a ph ylaxi s
Event s  of immediate (type I) hyper s en s itivity, including anaphylaxi s  (a s  defined in
Appendix B ), require that the inve s tigator or other s ite per s onnel inform appropriate s ponso r
study re p re s entative s  immediately, or n o later t h a n  24 h o u r s  of when he or s he become s
aware of the event. The de s ignated spon s or s tudy repre s entative work s  with the inve s tigato r  to
ensure that all relevant information i s  provided and entered in EDC. If the event i s  con s ide r ed
seriou s  it mu s t be reported a s  an SA E ( s ee S ection 5.6).
Signs  of immediate hyper s en s itivity include urticaria, pruritu s , angioedema, s kin ra s h,
difficulty breathing, and wheezing. P arent( s )/legal repre s entative s  will be provided a car d  with
this info r mation to aid in prompt identification and reporting of the s e s ign s . P arent( s )/legal
repre s entative s  will be in s tructed to immediately report the occurrence of any of the s e findings
to the s ite inve s tigator who s hould then report the event s  to appropriate s pon s or s tudy
repre s entative s  immediately, or n o later t h a n  24 h o u r s  of when he or s he become s  aware o f
the event.
[IP_ADDRESS] I mm un e Com p lex Di s ea s e
Event s  of immune complex di s ea s e (a s  defined in S ection 5.3.2 ) require that the inve s tigato r
or other site per s onnel inform appropriate s pon s or s tudy repre s entative s  immediately, or no
later t h a n  24 h o u r s  of when he or s he become s  aware of the event. The de s ignated s ponso r
study repre s entative work s  with the inve s tigator to en s ure that all relevant information i s
provided and entered into EDC. If the event i s  con s idered s eriou s  it mu s t be reported a s  an
SAE ( s ee S ection 5.6).
[IP_ADDRESS] T h rom b ocyto p e n ia
Event s  of thrombocytopenia (platelet count < 120,000 per µ L) require that the inve s tigato r  o r
other s ite per s onnel inform appropriate s pon s or s tudy repre s entative s  immediately, or n o la t er
than  24 h o u r s  of when he or s he become s  aware of the event. The de s ignated s pon s or s tudy
repre s entative work s  with the inve s tigator to en s ure that all relevant information i s  provided
and entered into EDC. If the event i s  con s idered s eriou s  it mu s t be reported a s  an S AE ( s ee
Section 5.6).
CONFIDENTIAL AND PROPRIETARY 68 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
5.7.[ADDRESS_408953] inform appropriate s pon s or repre s entative s  immediately, or n o later t h a n  24 h o u r s  o f
when he or s he become s  aware of it. The de s ignated s pon s or s tudy repre s entative work s  with
the inve s tigator to en s ure that all relevant information i s  provided and entered into EDC. If  the
event i s  con s idered s eriou s  it mu s t be reported a s  an S AE ( s ee S ection 5.6).
[ADDRESS_408954] i s  entered into the s tudy, a M edImmune repre s entative will review and
discu ss  the requirement s  of the protocol and related document s  with the inve s tigational s ta ff
and al s o train them in any s tudy- s pecific procedure s  and s y s tem( s ) utilized.
The P rincipal Inve s tigator will en s ure that appropriate training relevant to the s tudy i s  given to
all of these s taff, and that any new information relevant to the performance of thi s  s tudy is
forwarded to the s taff involved.
The P rincipal Inve s tigator will maintain a record of all individual s  involved in the s tudy
(medical ,  nur s ing, and other s taff).
6.[ADDRESS_408955] s  with the s tudy site,
including vi s it s  to:
P ro v ide information and s uppo r t to the inve s tigator( s )
Confirm that facilitie s  remain acceptable
 Con f irm that the inve s tigational team i s  adhering to the protocol, that data are being
accurately and timely recorded in the eCR Fs , that biological s ample s  are handled in
accordance with the Laboratory M anual and that s tudy drug accountability check s  a r e
being performed
P erform s ource data verification (a compari s on of the data in the eCR Fs  with the s ubject ’ s
medical record s  at the ho s pi[INVESTIGATOR_7117], and other record s  relevant to the s tudy)
including verification of informed con s ent of participating s ubject s . Thi s  will require
direct acce ss  to all original record s  for each s ubject (eg, clinic chart s )
En su re withdrawal of informed con s ent to the u s e of the s ubject’ s  biological s ample s  is
reported and biological s ample s  are identified and di s po s ed of/de s troyed accordingly, and
the action i s  documented, and r eported to the s ubject.
The M edImmune repre s entative will be available between vi s it s  if the inve s tigator( s ) or othe r
staff at the center need s  informatio n  and advice about the s tudy conduct.
CONFIDENTIAL AND PROPRIETARY 69 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
6.2.[ADDRESS_408956] wa s
followed through their la s t protocol- s pecified vi s it/a ss e ss ment (including telephone contact ) .
Subject s  will be con s idered not to have completed the s tudy if con s ent wa s  withdrawn or the
subject wa s  lo s t to follow-up ( s ee S ection s  4.1.5 and 4.1.6 ).
The end of the s tudy (“ s tudy completion ”) i s  defined a s  the date of the la s t protocol- s peci f ied
visit/a ss e ss ment (including telephone contact) for the la s t s ubject in the s tudy.
6.4 Data  Management
Data management will be performed by M edImmune Data M anagement s taff or other pa r ty
according to the Data M anagement P lan.
An electronic data capture s y s tem w ill be u s ed for data collection and query handling. The
inves tigator will en s ure that data are recorded in the eCR Fs  a s  s pecified in the s tudy protocol
and in accordance with the eCR F  in s truction s  provided.
The investigator en s ure s  the accuracy, completene ss , and timeline ss  of the data recorded and
of the pr o vi s ion of an s wer s  to data querie s  according to the Clinical S tudy Agreement. The
inves tigator will s ign the completed eCR Fs . A copy of the completed eCR Fs  will be archived
at the s t u dy s ite.
CONFIDENTIAL AND PROPRIETARY 70 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
6.[ADDRESS_408957]’ s
phys ician acce ss  to a medical monitor [ADDRESS_408958]’ s  health i s  deemed to be at ri s k. In thi s  s ituation, when a
subject pre s ent s  to a medical facility where the treating phy s ician or health care provider
require s  acce ss  to a phy s ician who ha s  knowledge of the inve s tigational product and the
clinical s tudy protocol and the P rincipal Inve s tigator i s  not available, the treating phy s ician o r
health care provider can contact a medical monitor through thi s  s y s tem, which i s  managed by
a third party vendor.
[ADDRESS_408959]’ s  informed con s ent. The informed con s ent
form will incorporate (or, in s ome ca s e s , be accompanied by a s eparate document
incorporating) wording that de s cribe s  how s ubject data will be collected, u s ed, and di s tributed
in compliance with relevant data protection and privacy legi s lation.
7.2 Ethics  and  Regulatory  Review
The IRB/IEC re s pon s ible for each site mu s t review and approve the final s tudy protocol,
including the final ver s ion of the In f ormed Con s ent F orm and any other written information
and/or material s  to be provided to the s ubject s . The IRB/IEC mu s t al s o approve all advertising
used to recruit s ubject s  for the s tud y . The inve s tigator i s  re s pon s ible for s ubmitting the s e
document s  to the applicable IRB/IEC, and di s tributing them to the s tudy s ite s taff.
The opi[INVESTIGATOR_1100]/IEC mu s t be given in writing. The inve s tigator mu s t provide a copy o f
the written approval to M edImmune before enrolment of any s ubject into the s tudy.
MedImmune s hould approve any s ub s tantive modification s  to the Informed Con s ent F orm that
are needed to meet local requirement s .
If required by [CONTACT_1295] s , the protocol mu s t be re-approved by [CONTACT_1201]/IEC annually.
Before the s tudy i s  initiated, M edImmune will en s ure that the national regulatory authority in
each country ha s  been notified and their approval ha s  been obtained, a s  required. M edImmune
will provide s afety update s /report s  according to local requirement s , including s u s pected
CONFIDENTIAL AND PROPRIETARY 71 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
unexpected s eriou s  adver s e reactio ns  where relevant, to regulatory authoritie s , IRB/IEC, and
principal inve s tigator s .
Each P rincipal Inve s tigator i s  re s pon s ible for providing report s  of any s eriou s  and unexpected
adver s e drug reaction s  from any other s tudy conducted with the inve s tigational product to the
IRB/IEC .  M edImmune will provide thi s  information to the P rincipal Inve s tigator s o that
he/she can meet the s e reporting requirement s .
7.[ADDRESS_408960] will be obtained through a written and verbal explanati o n
proce ss  that addre ss e s  all element s  required by [CONTACT_12212]/GC P . M edImmune will develop a c or e
informe d  con s ent form for u s e by [CONTACT_330892] s tigator s  in the clinical s tudy. M edImmune mu s t
approve any modification s  to the informed con s ent form that are needed to meet local
requirement s .
The P rincipal Inve s tigator( s ) at eac h  center will:
En s ure each s ubject’ s  legal guardian i s  notified that they are free to di s continue from the
study at any time
 En s ure that each s ubject’ s  legal guardian i s  given the opportunity to a s k que s tion s  and
allowed time to con s ider the in f ormation provided
En s ure each s ubject’ s  legal guardian provide s  s igned and dated informed con s ent be f o r e
conducting any procedure s pecifically for the s tudy
En s ure the original, s igned inf o rmed con s ent form( s ) i s /are s tored in the Inve s tigator ’ s
Study F ile
En s ure a copy of the s igned inf o rmed con s ent form i s  given to the s ubject’ s  legal gua r dian
 En s ure that any incentive s  for subject s  and/or their legal guardian s  who participate in the
study a s  well a s  any provi s ion s  for s ubject s  harmed a s  a con s equence of s tudy
participation are de s cribed in t h e informed con s ent form that i s  approved by [CONTACT_2717]/ I EC
7.4 Changes  to  the  Protocol  and  Informed  Consent  Form
Study procedure s  will not be changed without the mutual agreement of the inve s tigator s  and
MedImmune. Any change s  mu s t be documented in a s tudy protocol amendment.
For a s ub s tantial change to the protocol, M edImmune will di s tribute amended ver s ion s  o f  the
protocol to the P rincipal Inve s tigator( s ). Before implementation, amended protocol s  mu s t be
approve d  by [CONTACT_33149]/IEC ( s ee S ection 7.2) and reviewed a s  per local regulatory autho r ity
requirement s . The IRB/IEC mu s t al s o approve revi s ion s  to the informed con s ent form,
adverti s ing, and any other written information and/or material s  re s ulting from the change to
the protocol.
CONFIDENTIAL AND PROPRIETARY 72 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Any non- s ub s tantial change s  will be communicated to or approved by [CONTACT_9906]/IEC.
7.5 Audits  and  Inspections
Authorized repre s entative s  of M edImmune, a regulatory authority, or an IRB/IEC may
perform audit s  or in s pection s  at the center, including s ource data verification. The purpo s e o f
an audit or in s pection i s  to s y s tematically and independently examine all s tudy-related
activities and document s , to determine whether the s e activitie s  were conducted, and data we r e
recorded, analyzed, and accurately reported according to the protocol, GC P , guideline s  o f  the
ICH, and any applicable regulatory requirement s . The inve s tigator will contact M edImm u ne
immediately if contact[CONTACT_426] a regulatory agency about an in s pection at the s ite.
CONFIDENTIAL AND PROPRIETARY 73 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
8 REFERENCES
American Academy of P ediatric s . Updated guidance for palivizumab prophylaxi s  among
infant s  and young children at increa s ed ri s k of ho s pi[INVESTIGATOR_203256] s pi[INVESTIGATOR_696] s yncytial virus
infection. P ediatric s . 2014;134(2):415-20.
Blanken M O, Rover s  MM , M olenaar JM , Winkler- S ein s tra P L, M eijer A, Kimpen J L et al.
Dutch, R S V Neonatal Network. Re s pi[INVESTIGATOR_696] s yncytial viru s  and recurrent wheeze in healthy
preterm infant s . N Engl J  M ed. 2013;368(19):1791-9.
Carbonell-E s trany X, S imoe s  EA, Dagan R, Hall CB, Harri s  B, Hultqui s t M  et al.
Motavizumab for prophylaxi s  of re s pi[INVESTIGATOR_696] s yncytial viru s  in high-ri s k children: a
noninferiority trial. P ediatric s . 2010;125(1):e35-51.
Carroll KN, Gebret s adik T, Griffin MR, Wu P , Dupont WD, M itchel E F  et al. Increa s ing
burden and ri s k factor s  for bronchioliti s -related medical vi s it s  in infant s  enrolled in a s tate
health care in s urance plan. P ediatric s . 2008;122(1):58-64.
Frogel MP , S tewart DL, Hoope s  M , F ernande s  AW, M ahadevia PJ . A s y s tematic review o f
complia n ce with palivizumab admi n i s tration for R S V immunoprophylaxi s . J  M anag Care
Pharm. 2010;16(1):46-58.
Greenou g h A, Cox S , Alexander J , Lenney W, Turnbull F , Burge ss  S  et al. Health care
utilis atio n  of infant s  with chronic lung di s ea s e, related to ho s pi[INVESTIGATOR_36397] s ation for R S V infection.
Arch Dis Child. 2001;85(6):463-8.
Hall CB. Re s pi[INVESTIGATOR_696] s yncytial virus and parainfluenza viru s . N Engl J  M ed.
2001;34 4 (25):1917-28.
Hall CB, Weinberg GA, Iwane M K, Blumkin AK, Edward s  K M , S taat M A et al. The bu r den
of res pi[INVESTIGATOR_696] s yncytial viru s  infection in young children. N Engl J  M ed. 2009;360(6):[ADDRESS_408961] Diso r d
Drug Target s . 2012;12(2):92-7.
JCVI. J oint Committee on Vaccination and Immuni s ation. S tatement on immuni s ation fo r
respi[INVESTIGATOR_141876] r y s yncytial viru s . Department of Health, [LOCATION_008]. 2010a.
JCVI. J oint Committee on Vaccination and Immuni s ation: S tatement on immuni s ation f or
respi[INVESTIGATOR_141876] r y s yncytial viru s  - page [ADDRESS_408962] Di s  J . 2002;21 ( 7):629-32.
CONFIDENTIAL AND PROPRIETARY 74 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Madhi SA , Kuwanda L, Cutland C, Klugman K P . F ive-year cohort s tudy of ho s pi[INVESTIGATOR_059] f o r
respi[INVESTIGATOR_141876] r y s yncytial viru s  a ss ociated lower re s pi[INVESTIGATOR_330835] n . J
Clin Vir o l. 2006;36(3):215-21.
Maifeld S V, Ro B, M ok H, Chu M , Yu L, Yamagata R et al. Development of
electroc h emilumine s cent s erology a ss ay s  to mea s ure the humoral re s pon s e to antigen s  of
respi[INVESTIGATOR_141876] r y s yncytial viru s . P Lo S  One. 2016;11(4):e0153019.
Meiss ne r  HC. S elected population s  at increa s ed ri s k from re s pi[INVESTIGATOR_696] s yncytial viru s  infection.
Pediatr Infect Di s  J . 2003;22([ADDRESS_408963]): S 40-5.
Paramore LC, M ahadevia PJ , P iedra P A. Outpatient R S V lower re s pi[INVESTIGATOR_4416] s  among
high-ri sk  infant s  and other pediatric population s . P ediatr P ulmonol. 2010;45(6):578-84.
Parrott RH, Kim HW, Arrobio J O, Hode s  D S , M urphy BR, Brandt CD et al. Epi[INVESTIGATOR_623] o f
respi[INVESTIGATOR_141876] r y s yncytial viru s  infection in Wa s hington, D.C. II. Infection and di s ea s e with respect
to age, immunologic s tatu s , race an d  s ex. Am J  Epi[INVESTIGATOR_5541]. 1973;98(4):289-300.
Samp s on HA, M unoz- F urlong A, Campbell RL, Adkin s on N F , J r., Bock S A, Branum A et al.
Second s ympo s ium on the definition and management of anaphylaxi s : s ummary report--
Second N ational In s titute of Allergy and Infectiou s  Di s ea s e/ F ood Allergy and Anaphylaxis
Network s ympo s ium. J  Allergy Clin Immunol. 2006;117(2):391-7.
Shambaugh C, Az s hirvani S , Yu L, P ache J , Lambert S L, Zuo F  et al. Development of a high -
throughput re s pi[INVESTIGATOR_696] s yncytial viru s  fluore s cent focu s -ba s ed microneutralization a ss ay. Clin
Vaccine Immunol. 2017;24(12).
Shay DK, Holman RC, Newman R D , Liu LL, S tout J W, Ander s on L J . Bronchioliti s -
associated ho s pi[INVESTIGATOR_059] s  among U S  children, 1980-1996. J A M A. 1999;282(15):1440-6.
Shi T, M cAlli s ter DA, O'Brien KL, S imoe s  EA F , M adhi S A, Ge ss ner BD et al. Global,
regional, and national di s ea s e burden e s timate s  of acute lower re s pi[INVESTIGATOR_4416] s  due to
respi[INVESTIGATOR_141876] r y s yncytial viru s  in young children in 2015: a s y s tematic review and modelling
study. Lancet. 2017;390([ZIP_CODE]):946-58.
Stewart DL, Ryan K J , S eare J G, P in s ky B, Becker L, F rogel M . A ss ociation of R S V-related
hospi[INVESTIGATOR_330836]-compliance with palivizumab among commercially in s ured infa n ts: a
retro s pective claim s  analy s i s . B M C Infect Di s . 2013;[ZIP_CODE].
Stockman L J , Curn s  AT, Ander s on L J , F i s cher-Langley G. Re s pi[INVESTIGATOR_696] s yncytial viru s -
associated ho s pi[INVESTIGATOR_059] s  among infant s  and young children in the United S tate s , 1997-2006.
Pediatr Infect Di s  J . 2012;31(1):5-9.
CONFIDENTIAL AND PROPRIETARY 75 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Zhu Q, McLellan JS , Kallewaard NL, Ulbrandt ND, P ala s zyn s ki S , Zhang J  et al. A highly
potent extended half-life antibody a s  a potential R S V vaccine s urrogate for all infant s . S ci
Tran s l M ed. 2017;9(388).
CONFIDENTIAL AND PROPRIETARY 76 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Appendix  AProt o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
Additional  Safety  Guidance
Furt h er G u i d a n ce o n  t h e Defi n itio n  of a S erio us  A d ver s e Eve n t ( S AE)
Life threatening
‘Life-threatening ’ mean s  that the s ubject wa s  at immediate ri s k of death from AE a s  it
occurred or it i s  s u s pected that u s e or continued u s e of the product would re s ult in the
subject’ s  death. ‘Life-threatening ’ doe s  not mean that had an AE occurred in a more s eve r e
form it might have cau s ed death (eg, hepatiti s  that re s olved without hepatic failure).
Hospi[INVESTIGATOR_330837] n t treatment in an ER i s  not in it s elf a s eriou s  AE, although the rea s on s  for it may be
(eg, broncho s pa s m, laryngeal edema). Ho s pi[INVESTIGATOR_330804] s  and/or s urgical operation s  planned
before or during a s tudy are not con s idered AE s  if the illne ss  or di s ea s e exi s ted before the
subject wa s  enrolled in the s tudy, p r ovided that it did not deteriorate in an unexpected way
during the s tudy.
Importa n t M edical Event or M edical Intervention
Medical and s cientific judgment s hould be exerci s ed in deciding whether a ca s e i s  s erious in
situations where important medical event s  may not be immediately life threatening or result in
death, ho s pi[INVESTIGATOR_059], di s ability or incapacity but may jeopardize the s ubject or may req u i r e
medical intervention to prevent one or more outcome s  li s ted in the definition of s eriou s . These
should usually be con s idered a s  s eriou s .
Simply s toppi[INVESTIGATOR_100025] s u s pect drug doe s  not mean that it i s  an important medical event; medical
judgment mu s t be u s ed.
Example s  of s uch event s  are:
Angioedema not s evere enough to require intubation but requiring intravenou s
hydrocorti s one treatment
Hepatotoxicity cau s ed by [CONTACT_76475] (acetaminophen) overdo s e requiring treatment with
N-acetylcy s teine
Inten s ive treatment in an ER or at home for allergic broncho s pa s m
Blood dy s cra s ia s  (eg, neutrope n ia or anemia requiring blood tran s fu s ion) or convul s ions
that do not re s ult in ho s pi[INVESTIGATOR_330838] n t of S everity
Asse ss ment of s everity i s  one of the re s pon s ibilitie s  of the inve s tigator in the evaluation of
AEs and S AE s . The determination of s everity s hould be made by [CONTACT_132366] s tigator ba s ed u pon
medical judgment and the s everity categorie s  of Grade 1 to 5 a s  defined below.
CONFIDENTIAL AND PROPRIETARY 77 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Grade 1
Grade 2
Grade 3
Grade 4
Grade 5Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
An event of mild inten s ity that i s  u s ually tran s ient and may
requi r e only minimal treatment or therapeutic intervention. The
event doe s  not generally interfere with u s ual activitie s  of daily
living.
An event of moderate inten s ity that i s  u s ually alleviated with
additional s pecific therapeutic intervention. The event inte rf e r es
with u s ual activitie s  of daily living, cau s ing di s comfort but
poses  no s ignificant or permanent ri s k of harm to the s ubject.
A sev ere event that require s  inten s ive therapeutic intervention.
The event interrupt s  u s ual activitie s  of daily living, or
signi f icantly affect s  the clinical s tatu s  of the s ubject.
An event, and/or it s  immediate s equelae, that i s  a ss ociated with
an imminent ri s k of death.
Death a s  a re s ult of an event.
It is important to di s tingui s h between s eriou s  criteria and s everity of an AE. S everity i s  a
meas ure of inten s ity wherea s  s erio us ne ss  i s  defined by [CONTACT_330893] S ection 5.2. A Grade [ADDRESS_408964]. The following factor s  s hould be con s idered when deciding if there is a
“reas ona b le po ss ibility” that an AE may have been cau s ed by [CONTACT_132366] s tigational product.
Time Cour s e. Expo s ure to s u s pect inve s tigational product. Ha s  the s ubject actually
received the s u s pect inve s tigational product? Did the AE occur in a rea s onable tempo r al
relation s hip to the admini s tration of the s u s pect inve s tigational product?
Consi s tency with known inve s tigational product profile. Wa s  the AE con s i s tent with the
previou s  knowledge of the s u s pect inve s tigational product (pharmacology and toxicology )
or product s  of the s ame pharmacological cla ss ? OR could the AE be anticipated from its
pharmacological propertie s ?
De-challenge experience. Did the AE re s olve or improve on s toppi[INVESTIGATOR_330839] s u s pect inve s tigational product?
CONFIDENTIAL AND PROPRIETARY 78 of 80 T e mp late  18.0
MedImmun e
MEDI8897Prot o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
 No alternative cau s e. The AE cannot be rea s onably explained by [CONTACT_11693] s uch as
the underlying di s ea s e, other drug s , or other ho s t or environmental factor s .
 Re-challenge experience. Did the AE reoccur if the s u s pected inve s tigational product was
reintroduced after having been s topped? M edImmune would not normally recommend o r
support a re-challenge.
Lab o ratory te s t s . A s pecific laboratory inve s tigation (if performed) ha s  confirmed the
relation s hip?
In diffic u lt ca s e s , other factor s  could be con s idered s uch a s :
I s  thi s  a recognized feature of overdo s e of the inve s tigational product?
I s  there a known mechani s m?
Caus ality of ‘related’ i s  made if following a review of the relevant data, there i s  evidence f o r  a
‘reas onable po ss ibility’ of a cau s al r elation s hip for the individual ca s e. The expre ss ion
‘reas onable po ss ibility’ of a cau s al relation s hip i s  meant to convey, in general, that there a r e
facts  (evidence) or argument s  to s ugge s t a cau s al relation s hip.
The cau s ality a ss e ss ment i s  performed ba s ed on the available data including enough
information to make an informed j u dgment. With limited or in s ufficient information in the
case, it is likely that the event( s ) will be a ss e ss ed a s  ‘not related ’.
Caus al relation s hip in ca s e s  where the di s ea s e under s tudy ha s  deteriorated due to lack o f
effect s hould be cla ss ified a s  no rea s onable po ss ibility.
Relation s hip to P rotocol P rocedure s
The inve s tigator i s  al s o required to provide an a ss e ss ment of relation s hip of S AE s  to protocol
procedure s  on the S AE Report F orm. Thi s  include s  non-TE S AE s  (ie, S AE s  that occur prio r  to
the admini s tration of inve s tigational product) a s  well a s  TE S AE s . A protocol-related S AE
may occur a s  a re s ult of a procedure or intervention required during the s tudy (eg, blood
collectio n , wa s hout of an exi s ting medication). The following guideline s  s hould be u s ed b y
inves tigator s  to a ss e ss  the relation s hip of S AE s  to the protocol:
Protocol related:
Not protocol related:The event occurred due to a procedure/intervention that wa s  de s cribed
in the protocol for which there i s  no alternative etiology pre s ent in the
subject’ s  medical record.
The event i s  r elated to an etiology other than the procedure/
intervention that wa s  de s cribed in the protocol (the alternative etiology
must be documented in the s tudy s ubject’ s  medical record).
CONFIDENTIAL AND PROPRIETARY 79 of 80 T e mp late  18.0
MedImmun e
MEDI8897
Appendix  BProt o c o l  D5290C00005 (MEDLEY) Am e ndm e n t  1
 31M a r2021 ;  F i n al
National  Institute  of  Allergy  and  Infectious  Diseases  and
Food  Allergy  and  Anaphylaxis  Network  Guidance  for
Anaphylaxis  Diagnosis
Samp s on HA, M uñoz- F urlong A, Campbell RL, Adkin s on F N J r, Bock S A, Branum A, et al.
Second s ympo s ium on the definition and management of anaphylaxi s : S ummary report --
Second N ational In s titute of Allergy and Infectiou s  Di s ea s e/ F ood Allergy and Anaphylaxis
Network s ympo s ium. J  Allergy Clin Immunol. 2006;117:391-7.
National In s titute of Allergy and In f ectiou s  Di s ea s e and F ood Allergy and Anaphylaxi s
Network define anaphylaxi s  a s  a s eriou s  allergic reaction that i s  rapid in on s et and may cause
death. They recognize 3 categorie s  of anaphylaxi s , with criteria de s ignated to capture from
80% of ca s e s  (category 1) to > 95 %  of all ca s e s  of anaphylaxi s  (for all 3 categorie s ).
1Acute on s et of an illne ss  (minute s  to s everal hour s ) with involvement of the s kin, mucosal
tissue, or both (eg, generalized hive s , pruritu s  or flu s hing, s wollen lip s -tongue-uvula )
AND AT LEA S T ONE O F  T H E F OLLOWING
(a) Re s pi[INVESTIGATOR_330840] s e (eg, dy s pnea, wheeze-broncho s pa s m, s tridor, reduced peak
expi[INVESTIGATOR_10229] [ P E F ], hypoxemia)
(b) Reduced blood pre ss ure (B P ) or a ss ociated s ymptom s  of end-organ dy s function ( eg,
hypotonia [collap s e], s ync o pe, incontinence)
2Two or more of the following t h at occur rapi[INVESTIGATOR_330841] s ure to a likely allergen f or  that
patient (minute s  to s everal hour s ):
(a) I nvolvement of the s kin-muco s al ti ss ue (eg, generalized hive s , itch-flu s h, s wollen
lips-tongue-uvula)
(b) Re s pi[INVESTIGATOR_330840] s e (eg, dy s pnea, wheeze-broncho s pa s m, s tridor, reduced PE F ,
hypoxemia)
(c) Reduced B P  or a ss ociated s ymptom s  (eg, hypotonia [collap s e], s yncope,
incontinence)
(d) Per s i s tent ga s trointe s tinal symptom s  (eg, crampy abdominal pain, vomiting)
3Reduced B P  after expo s ure to k nown allergen for that patient (minute s  to s everal hou r s ) :
(a) I nfant s  and children: low s y s tolic B P  (age s pecific) or greater than 30% decrea s e in
systolic B P
CONFIDENTIAL AND PROPRIETARY [ADDRESS_408965] r onic s ignatu r e
Docu me n t Name: d5290c00005-c s p-ver s ion-2
Docu me n t Title:
Docu me n t I D:
Vers io n  La b el:D5290C00005 Clinical S tudy P rotocol Ver s ion 2
Doc ID-003966319
2.0 CURRENT LATE S T A PP ROVED
Server D a te S ig n ed b y
(dd-MMM-yyyy HH :mm  ‘ UTC ’ Z )
31-M ar-2 0 21 17:16 UTC
31-M ar-2 0 21 19:25 UTC
31-M ar-2 0 21 18:21 UTC
31-M ar-2 0 21 19:25 UTC
31-M ar-2 0 21 19:49 UTCMea n i n g of S ig n at u re
Author Approval
Content Approval
Content Approval
Content Approval
Content Approval
Note s : (1) Document details as sto r ed in ANG EL, an As t r aZeneca document management s y s tem.